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Abstract We have published extensively on the neuro-
genetics of brain reward systems with reference to the genes
related to dopaminergic function in particular. In 1996,
we coined “Reward Deficiency Syndrome” (RDS), to portray
behaviors found to have gene-based association with
hypodopaminergic function. RDS as a useful concept has
been embraced in many subsequent studies, to increase our
understanding of Substance Use Disorder (SUD), addictions,
and other obsessive, compulsive, and impulsive behaviors.
Interestingly, albeit others, in one published study, we were
able to describe lifetime RDS behaviors in a recovering addict
(17 years sober) blindly by assessing resultant Genetic Addic-
tion Risk Score (GARS™) data only. We hypothesize that
genetic testing at an early age may be an effective preventive
strategy to reduce or eliminate pathological substance and
behavioral seeking activity. Here, we consider a select number
of genes, their polymorphisms, and associated risks for RDS
whereby, utilizing GWAS, there is evidence for convergence
to reward candidate genes. The evidence presented serves as a
plausible brain-print providing relevant genetic information
that will reinforce targeted therapies, to improve recovery and
prevent relapse on an individualized basis. The primary driver
of RDS is a hypodopaminergic trait (genes) as well as epige-
netic states (methylation and deacetylation on chromatin
structure). We now have entered a new era in addiction med-
icine that embraces the neuroscience of addiction and RDS as
a pathological condition in brain reward circuitry that calls for
appropriate evidence-based therapy and early genetic diagno-
sis and that requires further intensive investigation.
Keywords Genetic Addiction Risk Score (GARS)™ .
Polymorphisms . brain reward circuitry . RewardDeficiency
Syndrome (RDS) . Neurogenetics
K. Blum (*) :M. S. Gold
Department of Psychiatry & McKnight Brain Institute, University of
Florida College of Medicine, Gainesville, FL, USA
e-mail: drd2gene@gmail.com
M. Oscar-Berman
Departments of Psychiatry, Neurology, and Anatomy &
Neurobiology, Boston University School of Medicine, and Boston
VA Healthcare System, Boston, MA 02118, USA
K. Blum
Department of Holistic Medicine, National Institute for Holist
Addiction Studies, North Miami Beach, FL, USA
K. Blum
Human Integrated Services Unit University of Vermont Center for
Clinical & Translational Science, College of Medicine, Burlington,
VT, USA
K. Blum
Dominion Diagnostics, LLC, North Kingstown, RI, USA
K. Blum
Department of Addiction Research & Therapy, Malibu Beach
Recovery Center, Malibu Beach, CA, USA
K. Blum
Department of Clinical Neurology, PATH Foundation, New York,
NY, USA
K. Blum :D. Barh
Institute of Integrative Omics and Applied Biotechnology, Nonakuri,
Purba Medinipur, West Bengal, India
K. Blum
IGENE, LLC, Austin, TX, USA
Z. Demetrovics
Department of Clinical Psychology and Addiction, Eötvös Loránd
University, Institute of Psychology, Budapest, Hungary
Mol Neurobiol
DOI 10.1007/s12035-014-8726-5
The Role of Dopaminergic Genetics in Reward
Dependence
Neurotransmitter interactions regulate brain reward circuitry
that result in the release of dopamine (DA) in the major loci
for feelings of well-being and reward, the nucleus accumbens
(NAc) part of the mesolimbic system of the brain. The inter-
relationship of at least four important neurochemical path-
ways: serotonergic, endorphinergic, GABAergic, and dopa-
minergic constitute the “brain reward cascade” (see Fig. 1) a
natural sequence of events that produce feelings of well being.
These activities including: the synthesis, vesicle storage, me-
tabolism, release, and function of neurochemicals [1] are
regulated by genes, and their expression, in terms of messen-
ger RNA-directed proteins. Thus, genetic testing is a potential
window that can be used to identify the specific neurochem-
istry of individuals and formulate the best treatment options
for them [1–13].
DA is a neurotransmitter with multiple important functions
including behavioral effects such as “pleasure” and “stress
reduction.” Simply stated, without the normal function of this
substance, an individual will suffer from cravings and have an
inability to cope with stress. Thus, genetic hypodopaminergic
brain function predisposes individuals to seek substances and
or behaviors that can be used to overcome this craving state by
activating the mesolimbic dopaminergic centers [4, 13]. Psy-
choactive substances like alcohol, psychostimulants and opi-
ates, and risky behaviors like gambling, overeating and thrill
seeking [16] induce the release of neuronal DA into the
synapse at the NAc, to overcome the hypodopaminergic state
of that individual. Temporary relief from the discomfort and a
pseudo sense of well-being is the product of this self-
medication [17]. Unfortunately, chronic abuse of psychoactive
substances leads to inactivation, or a downregulation, like for
example, inhibition of neurotransmitter synthesis, neurotrans-
mitter depletion, formation of toxic pseudo neurotransmitters,
and through structural receptor dysfunction. Therefore,
substance-seeking and pathological behaviors are both used
as a means of providing a feel-good response (a “fix”) to
lessen uncontrollable cravings. Individuals who possess re-
ward gene polymorphisms or variations, will, given environ-
mental insult be at risk for impulsive, compulsive, and addic-
tive behaviors. Reward Deficiency Syndrome (RDS) is a term
used to embrace and characterize these genetically induced
behaviors. Any and all of these pathological behaviors, as well
as psychoactive drug-abuse, are candidates for addiction in-
cluding tolerance and dependence. The behavior or drug of
choice by the individual is a function of both genes and
environmental factors like availability and peer pressure.
Brain Reward Cascade Explanation
DA is crucial to the maintenance of natural rewards while the
release of DA into NAc synaptic sites is a somewhat complex
cascade of reactive activity that involves neurotransmitters
and structures in the limbic system [1]. Blum and Kozlowski
first proposed the concept of a “brain reward cascade” in 1990
as a cascade of interactive events and mesolimbic function
that produces the net release of DA [1] (see Fig. 1). Simply,
the interaction of activities in the separate subsystems of the
brain’s reward circuitry combine into the much larger global
system, and reveal the cascade of neurotransmission, which
merges simultaneously and in a specific sequence.When these
systems work normally, they result in a feeling of pleasure,
well-being, and peace; an imbalance, or deficiency, on the
other hand, will cause the system to function abnormally,
displacing the sense of well-being with negative feelings like
anxiety, anger, and low self-esteem. The need to mask these
negative feelings leads to the use of substances such as alcohol
and narcotics, meaning that excessive desires are spurred by
the need for DA.
Fig. 1 Brain Reward Cascade
[14, 15]. In this cascade,
stimulation of the serotonergic
system in the hypothalamus leads
to the stimulation of delta/mu
receptors by serotonin to cause a
release of enkephalin. Activation
of the enkephalinergic system
induces an inhibition of GABA
transmission at the substania nigra
by enkephalin stimulation of mu
receptors at GABA neurons. This
inhibitory effect allows for the
fine-tuning of GABA activity.
This provides the normal release
of dopamine at the projected area
of the NAc [14, 15]
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The DA pathway arises in the ventral tegmental area (VTA)
and culminates in the DA D2 receptors on neurons located in
the cell membranes of in the hippocampus and the NAc. Blum
and Kozlowski [1] describe a process that begins in the
hypothalamus, where the excitatory activities of 5-HT-
releasing-neurons cause the release of met-enkephalin, an
opioid peptide. The opioid peptide regulates the activity of
neurons responsible for the release of gamma-aminobutyric
acid (GABA) the inhibitory neurotransmitter at the substantia
nigra. When DA-containing neurons in the VTA, and in
certain parts of the hippocampus via the amygdala, are
disinhibited, DA is allowed to be released into the NAc,
permitting the completion of the cascade. If the cascade is
functioning correctly, the reward sensation, or the feeling of
well-being, is experienced, provided certain basic genetic
conditions are fulfilled (see Fig. 1) [1]. However, when the
genes that govern the function of the brain reward cascade
have polymorphic variations, these risk alleles provide the
basis for therapeutic targets.
RDS and Genetic Antecedents
The development of a blueprint for identifying certain candi-
date genes and polymorphisms that could negatively impact
DA release is based on this understanding of the brain reward
cascade [2]. Many genes are involved, and it has been ade-
quately established in association studies and animal re-
search literature that, for example, polymorphisms of the
serotonergic-2 A receptor (5-HTT2a), DA D2 receptor
(DRD2), and the catechol-O-methyl-transferase (COMT)
genes (see Genetic Addiction Risk Score (GARS) test), pre-
dispose individuals to aberrant RDS behaviors. These behav-
iors include craving not only for drugs and alcohol but eating
and other addictive behaviors such as pathological gambling
(see Table 1) [3]. Gene polymorphisms of both 5-HT and DA
can result in significantly lower than normal receptor
densities. A COMT gene polymorphism can result in in-
creased catabolism of synaptic DA and subsequent reduction
of DA function. These are three examples of how the identi-
fication of polymorphisms on these three genes can provide a
window into an impaired brain reward cascade, and the iden-
tification of individuals at high risk can be accomplished.
Based on a published [11] mathematical Bayesian approach,
it was found that individuals who carry the Taq A1 polymor-
phisms of theDRD2 have a 74.4% chance of developing RDS
behaviors, given an environmental insult and epigenetic ef-
fects (see Table 1).
Genomics: Evidence-Based Studies
In general, inconsistencies in the literature involving associ-
ation studies using single gene analysis prompted Conner [4]
and others to evaluate a number of dopaminergic gene
polymorphisms as predictors of drug use in adolescents.
We cannot ignore the importance of neurochemical mecha-
nisms involved in drug-induced relapse behavior, as sug-
gested by Bossert et al. [5] for understanding the interaction
of multiple genes and environmental elements. Using a drug
relapse model previously shown to induce relapse by re-
exposing rats to heroin-associated contexts, these investiga-
tors found that after extinction of drug-reinforced responding
in different contexts, re-exposure reinstated heroin seeking.
This effect was diminished by inhibition of GABA trans-
mission in the VTA and medial accumbens shell and com-
ponents of the mesolimbic DA system; this process en-
hances net DA release into the NAc. Indeed, this fits well
with Li’s Knowledgebase for Addiction-Related Genes
(KARG) addiction network map [6] (see Fig. 2). Li et al.
[6] also stressed the view that drug addiction is a serious
problem worldwide with strong genetic and environmental
influences. And that a variety of technologies were used to
discover genes and pathways that underlie addiction
Table 1 Reward deficiency syndrome behaviors (linked with DSM 5)
Addictive behaviors Impulsive behaviors Obsessive compulsive
behaviors
Personality
disorders
Substance related Non substance related Spectrum disorders Disruptive impulsive
Alcohol Thrill seeking (novelty) Attention-deficit hyperactivity Anti-social Body dysmorphic Paranoid
Cannabis Sexual sadism Tourette and tic Syndrome Conduct Hoarding Schizoid
Opioids Sexual masochism Autism Intermittent explosive Trichotillomania (hair pulling) Borderline
Sedatives/hypnotics Hypersexual Oppositional defiant Excoriation (skin picking) Schizotypal
Stimulants Gambling Exhibitionistic Non-suicidal self-injury Histrionic
Tobacco Internet gaming Narcissistic
Glucose Avoidant
Food Dependant
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however, each individual technology can be biased and
incomplete. Li and his colleagues integrated evidence from
peer-reviewed publications 2,343 items between 1976 and
2006 that inked genes and chromosomal regions to addiction
by single-gene strategies, microarray, proteomics, or genetic
studies. They identified 1,500 human addiction-related genes
and developed the first molecular KARG (http://karg.cbi.
pku.edu.cn), with a friendly web interface and extensive
annotations. Their meta-analysis of 396 genes, each support-
ed by two or more independent items of evidence, leads to
the identification of 18 molecular pathways that were statis-
tically significant and covered both upstream signaling
events and downstream effects. For four different types of
addictive drugs and five significant molecular pathways
including two new ones; GnRH signaling pathway and gap
junction were identified as common pathways that may
underlie shared rewarding and addictive actions. In a hypo-
thetical common molecular network for addiction, they con-
nected the common pathways which linked all of these
genes, to both the glutaminergic and dopaminergic
pathways.
Following the initial finding of Blum et al. in 1990 [7]
showing a positive association of the single gene DRD2
polymorphism in chromosome 11 and severe alcoholism,
replication, although favorable has, to date, been fraught with
inconsistent results. This has also been true for other complex
behaviors [9] when gene-gene and gene-environment interac-
tions are tested the idea that complex gene-relationships may
account for inconsistent findings across many different single
gene studies is supported [8]. The reasons for inconsistencies
in trying to predict drug use are many and varied: they include
single gene analysis, poorly screened controls, stratification of
population, personality traits, co-morbidity of psychiatric dis-
orders, gender-base differences, positive and negative life
events, and neurocognitive dysfunctioning and epigenetic
effects [6, 7].
In order to gain a more complex but stronger predictive set
of genetic antecedents rather than continue to evaluate single
gene associations, we embarked on a study to evaluate multi-
ple candidate genes, especially those linked to the Brain
Reward Cascade to predict future drug abuse [1] and identify
risk for hypodopaminergic functioning. Although exploratory,
the goal is to develop an informative panel based on numerous
known risk alleles to provide treatment facilities a means of
stratifying patients entering treatment as having a high, mod-
erate, or low, genetic risk prediction.
As noted above, an association between dopaminergic
gene polymorphisms and addictive, compulsive, and impul-
sive behaviors classified as RDS has been revealed in numer-
ous studies. We evaluated subjects derived from two families
for a potential association with polymorphisms of the DA D2
receptor gene (DRD2), DA D1 receptor gene (DRD1), DA
transporter gene (DAT1), and DA beta-hydroxylase gene
(DBH). This association if found would demonstrate the rel-
evance of a generalized RDS behavior set, as the phenotype.
An experimental group derived from up to five generations
of two independent multiple-affected families n=55 were
genotyped and compared to very rigorously screened controls.
In addition to these subjects, data related to RDS behaviors
was collected from 13 deceased family members. The geno-
typed family members carried the DRD2 Taq1 allele at 78 %
the DAT110/10 allele at 58%, the DBHB1 allele at 66%, and
the DRD1 A1/A1 or the A2/A2 genotypes at 35 %. Interest-
ingly, all probands (n=32) from Family A genotyped for the
Fig. 2 KARG an addiction
network map [6]
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DRD2 gene carried the TaqA1 allele (100%). The experimen-
tal positive rate for the DRD2 Taq1 allele with an odds ratio of
103.9 (12.8, 843.2) was significantly greater (X2=43.6,
P<0.001). The experimental positive rate for the DAT1 10/
10 allele with an odds ratio of 2.3 (1.2, 4.6) was also signif-
icantly greater (X2=6.0, P<0.015). Between the experimental
and control positive rates of the DBH, DRD1 A1/A1, or A2/
A2 genotypes no significant differences were observed [18].
Patients genetic risk for drug-seeking behavior needs
to be evaluated prior to, or upon entry to chemical
dependency programs. The importance of genotyping to
establish genetic severity for patients undergoing treat-
ment and in danger of relapse is described below in the,
as yet, unpublished results from a study of the data from
Comprehensive Analysis of Reported Drugs (CARD).
We have followed up by evaluating a panel of genes
and associated polymorphisms termed GARS in patients
with RDS behaviors attending two treatment centers. In
this and other studies, we use the GARS for purposes of
study identification and commercial testing [9–11].
To determine risk severity of 72 addicted patients, the
percentage of prevalence of selected risk alleles was calculat-
ed to provide a severity score. We genotyped the patients
using a nine reward genes and their polymorphisms (F=18
alleles; M=17 alleles). This panel included: DRD 2, 3, 4;
MOA-A; COMT; DAT1; 5HTTLLR; OPRM1; and GABRA3
genes. The three severity ratings were: Low severity=1–36%;
moderate severity=37–50 %, and high severity=51–100 %.
We studied two distinct treatment populations: Group 1
consisted of 37 addicts from a holistic addiction treatment
center in North Miami Beach, Florida, and Group 2 consisted
of 35 addicts from Malibu Beach Recovery Center [12]. We
are in the process of analyzing 393 subjects using a multi-
centered approach across the USA.
However, in the following unpublished experiment, we
found risk stratification of the 72 genotyped patients to be as
follows: 27 % low risk; 74 % moderate risk, and 4 % severe
risk. We are exploring potential risk correlation with the
Addiction Severity Index (ASI). Preliminary statistical analy-
sis reveals that with N=277, we found a significant trend
whereby allelic risk above the means score associated with
the ASI Alcohol Risk Severity Score at P<0.07 (one sided P).
Unlike CARD, the GARS could provide potential correlations
to ASI to at least the alcohol risk composite score. If this
finding is upheld through larger populations, it unequivocally
demonstrates that objective genetic polymorphisms could pre-
dict clinical outcomes.
We are cognizant that, as the next steps in identifying
candidate gene polymorphic associations with RDS as the
overall phenotype, wemust carefully dissect epigenetic effects
such as miRNA and subsequent methylation and/or
deacetylation of attached chromatin markers leading to altered
gene expression in spite of DNA polymorphisms.
CARD™ Provides a Rationale for Genetic Testing
The primary reason to include some brief information regard-
ing CARD is to provide a clear indication that genetic testing
may provide valuable information about the risk that drives
relapse. In an unpublished study but submitted article from
our laboratory, a statistical analysis of unidentifiable data from
a computer-based program called CARDwas used to evaluate
treatment adherence in a large clinical cohort from across a
number of eastern states in America. This study consisted of
5,703 patients and 11,403 specimens, in various treatment
settings across six eastern states. We found significant levels
of both non-compliance and lack of abstinence (risk for re-
lapse) during treatment. The CARD engine addresses issues
of metabolism as well as contaminants in the production
processes of some formulations. It addresses multi-faceted
scenarios within and across drug classes, often involving the
state of multiple analytes in order to reach a conclusion for
each self-reported or prescribed drug. It evaluates thousands
of rule sets to determine if the statement associated with each
rule set is applicable to the specimen test results and reported
drugs that are analyzed.
We are proposing a paradigm shift on the basis of these
studies, whereby the predisposition to a risk for RDS (the true
phenotype) can be accurately determined by utilizing GARS,
and treatment outcome can be assessed by utilizing CARD.
These results confirm the putative role of dopaminergic poly-
morphisms in RDS behaviors.
The Addiction Phenotype and the Need for Super
Controls
The family-based study [18] demonstrates the importance of a
nonspecific RDS phenotype and informed an understanding of
how evaluating single subset of RDS behaviors, like for exam-
ple, Tourette’s may lead to spurious results. Rather, the adop-
tion of a nonspecific reward phenotype may be useful in future
association and linkage studies involving neurotransmitter gene
candidates as utilized in GARS. The putative role of dopami-
nergic polymorphisms in RDS behaviors is supported by the
results [18], although linkage analysis is necessary and the
sample size was limited. We believe that using a nonspecific
reward phenotype in future association and linkage studies that
involve dopaminergic polymorphisms and other neurotransmit-
ter gene candidates may be a necessary paradigm shift.
This underscores the problem concerning appropriate con-
trols. While thousands of studies have associated the various
reward gene risk polymorphisms for all types of addictive
behaviors (including drugs, smoking, alcohol, gambling,
sex, shopping) against putative controls, there remains a real
need to develop super controls whereby the true phenotype is
not just drug addiction per se but the absence of any RDS
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behavior. To suggest that researchers can provide accurate
data by enlisting comparison individuals who are from an
unscreened general population as controls, is fraught with
an inappropriate and potentially inaccurate assessment. In
one, example, assessing the DRD2 A1 allele, we found
that while screened controls (eliminating drug and alcohol
abuse) in over 3,000 subjects showed a prevalence of
approximately 26 %; when we eliminated all RDS be-
haviors in the probands and family surprisingly we
found the DRD2 A1 allele prevalence to be only 3 %
[19]. In the current GARS test being cognizant of this
issue, we utilize the recognized method of counting risk
alleles to provide addiction risk. Below, we provide a
chart showing the remarkable Pub Med (3-16-14) list of
articles published on each independent gene involving
risk polymorphisms in RDS behavior and controls
(Fig. 3).
Theoretical Implications: Substance Abuse and Pain
Medications
Understanding that there is a thread between opioid prescribed
compounds for pain and addiction liability especially in sub-
jects genetically predisposed to RDS risk provides the ratio-
nale to address this growing epidemic globally. The GARS
test modified for pain clinics provides an analysis of about 14
genes and associated risk alleles. Thousands of studies in peer
reviewed scientific journals have revealed significant associ-
ations between certain reward genes, with reward circuitry
imbalances in the brain and risk for high substance seeking
behavior. The predictive value for just one gene such as the
DA D2 receptor gene is as high as 74.4 % as described by
Blum et al. [12]. Simply, the occurrence or absence of these
single nucleotide polymorphisms may determine a patient’s
predisposition to potential treatment outcome and relapse. In
addition to addiction risk, it may help guide the physician in
determining the use of chronic opioid therapy, and a rationale
for continuing urine monitoring consistent with the American
College of Occupational and Environmental Medicine
(ACOEM) guidelines. Most importantly, ACOEM suggests
that genetics are an important factor in pain management, and
according to the National Institute on Drug Abuse (NIDA), as
well as the American Society of Addiction Medicine
(ASAM), genes are responsible for a 60 % contribution to-
ward addictive behaviors. Not surprisingly, according to the
American Pain Society, a physician’s ability to predict an
opioid abuser is no better than chance (50 %). In fact,
Bornstein’s group [20] found that when clinicians’ only urine
test patients suspected of medication misuse, they are missing
a significant group; up to 72 % and are quick to make wrong
judgments. The ACOEM guidelines on Chronic Opioid Ther-
apy suggest “screening for risk of addiction should be per-
formed before starting a long-term opioid treatment in patients
with chronic pain”, thus providing the physician with clues
about the necessity for increased attention in susceptible pa-
tients. If opioid treatment results in pain control, better func-
tioning, and improved health-related quality of life, the treat-
ment should be continued, even in patients susceptible for
addiction. However, these patients will need special attention
with a focus on compliance, abstinence from other drugs of
abuse and with discussion of the potential consequences of
chronic treatment of pain with opioids.
Although the principal pain pathways ascend to the brain
from the dorsal horn of the spinal cord the control of sensitiv-
ity to pain may reside in the mesolimbic system of the brain at
the reward center, where gene polymorphisms may impact
pain tolerance and/or sensitivity. These polymorphisms may
associate with a predisposition to pain intolerance or tolerance
to pain. It is hypothesized that the identification of certain
gene polymorphisms may provide a unique therapeutic target
to assist in pain treatment. Thus, testing for certain candidate
genes like the mu receptors and PENK could assist in the
design of pharmacogenomic solutions personalized to each
patient and guided by their unique genetic makeup [10], with
potential for improvement in clinical outcomes [11].
4833
3384
1892
1407
1391
3670
698
1028
2065
1031
1536
1346
6079
SEROTONIN RECEPTOR 2a/c
SEROTONIN TRANSPORTER
COMT
MONAMINE OXIDASE–A 
DOPAMINE D1 RECEPTOR
DOPAMINE D2 RECEPTOR
DOPAMINE D3 RECEPTOR
DOPAMINE D4 RECEPTOR
DOPAMINE TRANSPORTER
DOPAMINE -BETA -HYDROYXALASE
OPIOID RECEPTOR
GABA RECEPTOR
CYTOCHROME P450 SYSTEM
Fig. 3 This is a list of Pub Med
articles that associate
polymorphisms of reward genes
with risk of RDS behaviors. For
each gene, there are many
polymorphisms, and there are
multiple receptors for each listed
transmitter. The DRD2 gene is the
most widely studied as a single
receptor type. Reward Gene
Publications 3/16/2014
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Understanding the role of neurogenetics in pain relief,
including pharmacogenomics and nutrigenomic aspects, will
pave the way to better treatment for the millions suffering
from both acute and chronic pain. We now know that dopa-
minergic tone is involved in pain sensitivity mechanisms and
even buprenorphine outcome response. The identification of
certain gene polymorphisms as unique, therapeutic targets
may assist in the treatment of pain. Pharmacogenetic testing
for certain candidate genes, like mu receptors and PENK, is
proposed, as a means to improve clinical outcomes by the
provision of treatment. The use of GARS, as described above,
to identify clients with high addiction risk by providing valu-
able information about genetic predisposition to opioid addic-
tion, could become an important frontline approach, on ad-
mission to pain clinics.
One notable study evaluated the role of both mu-opioid
receptors (MORs) and delta-opioid receptors (DORs) two
genes expressed in the VTA that may be involved in the
addictive properties of opiates. Researchers David et al. [21]
found that intra-VTA morphine self-administration was
abolished in knockout MOR gene mice at all doses tested.
While male and female WTand DOR−/−mice exhibited self-
administration similarly, however, this behavior was disrupted
without triggering physical signs of withdrawal by the admin-
istration of Naloxone (4 mg/kg) to WTand DORmutants. An
increase in foswas associated with Morphine ICSAwithin the
NAc, striatum, limbic cortices, amygdala, hippocampus, lat-
eral mammillary nucleus, and the ventral posteromedial thal-
amus where high levels of fos were expressed exclusively in
self-administering WT and DOR−/− mice. Abolition of mor-
phine reward inMOR−/−mice was associated with a decrease
in fos positive neurons in the mesocorticolimbic DA system,
amygdala, hippocampus (CA1), lateral mammillary nucleus,
and a complete absence within the ventral posteromedial
thalamus. David et al. [21] concluded that (a) ventral
posteromedial thalamus MORs, but not DORs, are critical
for morphine reward and (b) the role of VTA-thalamic pro-
jections in opiate reward warrants further exploration.
Moreover, clinical and laboratory studies have indicated
that the MOR gene contributes to inheritable vulnerability to
the development of opiate addiction. Polymorphisms that
occur naturally have been identified in the MOR gene. Sub-
stitutions occur at high allelic frequencies (10.5 and 6.6 %) in
two coding regions single nucleotide polymorphisms (SNPs),
the A118G and C17T respectively, of the MOR gene. These
SNPs cause amino acid changes in the receptor that impact on
an individual’s response to opioids and can influence in-
creases or decreases in vulnerability to opiate addiction [22].
Thus, in response to beta-endorphin in cellular assays, the
A118G substitution encodes a variant receptor with differ-
ences in binding and signal transduction [22]. Finally, to
firmly establish the role of MOR in reward and response to
buprenorphine, Ide et al. [23] assessed buprenorphine anti-
nociception by hot-plate and tail-flick tests, and found that it
was significantly reduced in heterozygous mu-opioid receptor
knockout (MOR-KO) mice and abolished in homozygous
MOR-KO mice. Buprenorphine, on the other hand, was able
to establish a conditioned place preference in homozygous
MOR-KO, although as the number of copies of wild-type mu-
opioid receptor genes was reduced, the magnitude of place
preference was reduced. This study revealed that mu-opioid
receptors mediate most of analgesic properties of
buprenorphine [23]. We are proposing that to determine pa-
tient addiction liability, genetic testing should be incorporated
into the beginning of Occupational Medical Clinic programs
to reduce iatrogenic opioid prescription addiction, and should
include both opioid and dopaminergic risk alleles.
Explanation of Single Nucleotide Polymorphisms
RDS-associated SNPs can be identified by any suitable meth-
od, including DNA sequencing of patients diagnosed with one
or more RDS behaviors. After validation, newly identified
RDS-associated SNPs can be used in the test. As will be
appreciated, once identified and validated, the presence, if
any, of one or more RDS-associated SNPs in the nucleic acids
derived from a biological sample taken from a patient can be
determined using any suitable now known or later-developed
assay, including those that rely on site-specific hybridization,
restriction enzyme analysis, or DNA sequencing. Table 2 lists
a number of particularly preferred RDS-associated SNPs,
whereby, the detection of which can be used for the GARS
test.
Serotonin (5-Hydroxytriptamine5-HT) Genes
(2AReceptor1438G/a)
Serotonin, also known as 5-hydroxytryptamine or 5-HT, is a
neurotransmitter and peripheral NH2 signal mediator that was
discovered in the late 1940s. By the early 1950s, neurotrans-
mitter function was identified in the central nervous system of
animals. In the late 1950s, there was evidence for 5-HT
receptor peripheral heterogeneity, and by 1979, 5-HT binding
sites were identified in the brain: 5-HT1 and 5-HT2. 5-HT 2A
receptor (5-HT2A) is one of several proteins to which 5-HT
binds when brain cells communicate. 5-HT receptors located
on the membranes of nerve and other cell types mediate the
effects of 5-HT as the endogenous ligand. 5-HT receptors are
heptahelical; G protein coupled seven trans-membrane recep-
tors, activated by an intracellular second messenger cascade
except for the 5-HT3 receptor, a ligand gated ion channel. The
5-HT receptor contains 471 amino acids in rats, mice, and
humans and is widely distributed in peripheral and central
tissues. 5-HT receptors mediate contractile responses in a
Mol Neurobiol
series of vascular smooth muscle preparations. In addition,
platelet aggregation and increased capillary permeability fol-
lowing exposure to 5-HT have been linked to 5-HT receptor-
mediated functions. Centrally, these receptors are located
principally on cells in the cerebral cortex, claustrum, and basal
ganglia. 5-HT receptors reduce cyclic adenosine mono-
phosphate (cAMP) and modify the activity and release
of other neurotransmitters like glutamate, enkephalin, DA,
and GABA. 5-HT2A receptors increase glutamate activity of
in many areas of the brain, some of the other 5-HT receptors
have the effect of suppressing glutamate. The therapeutic
actions that result from increased stimulation of 5-HT recep-
tors in anti-depressant and anxiolytic treatments seems to be
opposed by increased stimulation of the 5-HT2A receptors.
Serotonin Receptors (2A) Genetics
Everyone inherits two copies of the 5-HT2A receptor gene,
one from each parent. Small differences in the chemical se-
quence results, in some people having an adenine (A),
switched at the same point for a guanine (G). So a subject
can have gene types AA, AG, or GG. According to the US
Department of Health and Human Services National Institutes
of Health, “whether depressed patients will respond to an
antidepressant depends in part, on which version of a gene
they inherit.” The chance of a positive response to an antide-
pressant increase by up to 18 % in those who have two copies
of one version of a gene that codes for a component of brain
mood-regulation. It is well known that polymorphisms at the
5-HT2A receptor gene vary in terms of frequency, for exam-
ple, Whites have six times more of the minor allelic version
compared to Blacks. These and other findings add to evidence
that the component is a receptor for chemical antidepressant
action. Serotonergic genes have been also associated with
suicide ideation, trauma in children, and criminality [24, 25].
Specifically related to chemical dependencies, these partic-
ular genes have been associated with heroin dependence. The
5-HT2A-1438A allele was significantly more common in
heroin dependent patients than controls [0.55 and 0.45, re-
spectively; corrected P=0.042]. An interaction between
A-1438G of 5-HT2A and 5-HTT polymorphisms was ob-
served, in the presence of short 5-HTTLPR alleles and 12-
repeat 5-HTT VNTR the association between heroin depen-
dence and the −1438AAvs. AG/GG genotypes was enhanced
[24.8 % in heroin-dependent patients vs. 12.6 % in controls;
Table 2 RDS-associated SNPs
Gene Risk allele Comment
Dopamine D1 (DRD) 48A G normal
Dopamine D2 (DRD2) A1 A2 normal
Dopamine D3 (DRD3) C T normal
Dopamine D4 (DRD4) 7R 4R normal
Dopamine Transporter (DAT1) 9R = Fast uptake
10R = slow uptake
Fast DAT could result in hypodopaminergic and slow could result in hyper
dopaminergic
Serotonin Transporter (5HTTLLR) S Count S not L
Catechol-O-methyl-transferase (COMT) G The G allele = Val substation that cause the enzyme COMTwhich breaks
down Dopamine in the synapse too fast. This could also lead to
hypodopaminergic trait. The A = Met = normal
Mu opiate receptor (OPRM1) G The G allele whereby G = ASP this contributes to addiction to opiates and
alcohol. A = ASN normal. Another name is MOR-Mu opiate receptor
GABA A receptor subunit (GABRA3) 181 This 181 snp reduces the sensitivity of the GABA receptor and as such
increases the chance for alcoholism and other drugs of abuse. It increases
risk for stress induction, which can also cause relapse
MAOA uVNTR 4R = Fast uptake
3R = slow uptake
This is the strange gene. It sits on the mitochondria in the neuron. MAO is
involved in the breakdown of dopamine and serotonin. The 4R increases
the breakdown and 3R slows the breakdown. Since the gene sits on the X
chromosome not the Y chromosome females are XX and males are XY.
This means that females have two alleles to count andmales only have one
Serotonin 5HTA2 Receptor C Alcohol dependent (AD) patients homozygous for C allele had significantly
lower age at onset of alcohol problems than subjects having at least one T
allele. The results suggest a potential role of the T102C HTR2A
polymorphism in development of alcohol dependence
Serotonin 5HTA2 Receptor 1438A allele Another polymorphism the 5-HT (2A) -1438A allele was significantly more
common in patients than controls [0.55 and 0.45, respectively; corrected
P=0.042, OR=1.51 (95 % CI=1.13–2.03)]
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corrected P=0.045] [26]. Moreover, genetic analyses showed
that the frequency of 102C allele and C102C genotype in
alcoholic subjects was significantly higher than in controls.
In addition, alcoholic patients homozygous for C allele had
alcoholic problems at significantly earlier age of onset than
subjects having at least one T allele. These results point to the
possibility of a role for the T102C HTR2A polymorphism in
development of alcohol dependence and even relapse [27, 28].
Additionally, 5-HT2A, and 5-HT2C receptors that innervate
the DA meso-accumbens pathway may play a prominent role
in the behavioral effects of cocaine [29]. Smoking behavior is
influenced by genetic factors affecting the dopaminergic sys-
tem, and dopaminergic polymorphisms have been linked to
smoking habits [30]. Since this T102C polymorphism of the
5-HT2A receptor gene modulates the mesolimbic DA system
and is associated with reduced receptor gene expression, the
purpose of one study [31] was to investigate the relationship it
has to tobacco use. The T102C polymorphism was found to
be associated with maintenance, but not with the initiation of
the smoking habit. The CC genotype was more frequent in
current smokers than in never- or former-smokers (chi2=
6.825, P=0.03) with an odds ratio of 1.63, 95 % CI 1.06–
2.51. Interestingly, Nichols et al. [32] found that the gene
response to LSD was quite dynamic. The expression of some
genes increased rapidly and decreased rapidly while other
genes changed more gradually. Dose-response studies showed
two classes: (1) gene expression maximally stimulated at
lower doses, and (2) gene expression that continued to rise
at the higher doses. In a series of experiments that used
receptor specific antagonists, the role of the 5-HT1A and 5-
HT2A receptors inmediating the increases in gene expression,
was examined and found that the 5-HT2A receptor activation
was responsible for the majority of expression increases.
5-HTTLPR (Serotonin Transporter-Linked Polymorphic
Region)
The human 5-HT transporter is encoded by the SLC6A4 gene
on chromosome 17q11.1-q12. This is the site for cellular
reuptake of 5-HT and a site where many drugs with central
nervous system effects are activated. They include therapeutic
agents like antidepressants and psychoactive drugs of abuse
like cocaine. The 5-HT transporter has a prominent role in the
metabolic cycle of many antidepressants, antipsychotics, an-
xiolytics, anti-emetics, and anti-migraine drugs. Higher ex-
pression of brain 5-HTT is associated with the (long allele)
insertion variant compared to the (short allele) deletion vari-
ant. The results of some studies show that long allele is
responsible for increased 5HT transporter mRNA transcrip-
tion in human cell lines. Further, this may be due to the A-
allele of rs25531, so that subjects with the long-rs25531 (A)
allelic combination (LA) have higher levels, with the long-
rs25531(G) earners have levels more similar to short-allele
carriers. Saiz et al. [26] found an excess of -1438G and 5-
HTTLPR L carriers in alcoholic patients in comparison to the
heroin dependent group, the polymorphisms A-1438G and 5-
HTTLPR also distinguished, alcohol from heroin dependent
patients. The association of -1438A/G was especially pro-
nounced with alcohol dependence when 5-HTTLPR S/S was
present, less evident with 5-HTTLPR L/S, and not present
with 5-HTTLPR.
The 5-HT transporter, encoded by the SLC6A4 gene, in-
fluences the synaptic actions of 5-HT and is responsive to
stress hormones. In fact, the risk for suicidal behavior in CT
exposed individuals is independently affected by the 5′ and 3′
SLC6A4 functional variants [25]. National Longitudinal
Study of Adolescent Health data shows that there is a signif-
icant gene-environment correlation between 5-HTTLPR and
neglect for females only. Findings also reveal that 5-HTTLPR
is associated with an increased risk of neglect for females and
neglected females’ risk of abusing marijuana [33]. Socializa-
tion scores were significantly lower in males (greater
sociopathy), with the L′L′ genotype (i.e., those homozygous
for the L (A) allele) than males who carried the S′ allele (P=
0.03). In contrast, women with the S′S′ genotype tended to
have a lower Socialization Index on the California Psycho-
logical Inventory than women with one copy of the L′ allele
(P=0.07) and lower socialization scores than womenwith two
L′ alleles (P=0.002). The tri-allelic 5-HTTLPR polymor-
phism had opposite effects on socialization scores in men than
women with alcohol use disorders [34].
The genotype coding for low 5-HTT expression is associat-
ed with a better opioid analgesic effect, while the 5-HTTLPR s-
allele has been associated with higher risk of developing chron-
ic pain conditions. Downregulation of 5-HT1 receptors has
been associated with the s-allele, and Kosek et al. [35] have
suggested that individuals have an increased analgesic response
to opioids during acute pain stimuli with a desensitization of 5-
HT1 receptors, but may still be at increased risk of developing
chronic pain conditions. The risk of alcohol dependence and
co-occurring clinical features is increased in the presence of the
short (S) allele of the 5-HT transporter gene promoter polymor-
phism (5-HTTLPR). While no other factor that were measured
played a significant role, the S allele was significantly associ-
ated with relapse (P=0.008). Thus, in abstinent alcohol-
dependent patients the risk of relapse may be influenced by S
allele of the 5-HTTLPR polymorphism, possibly through inter-
mediate phenotypes [36].
Catecholamine-O-Methyltransferase (COMT)
Val158Met Polymorphism
Catechol-O-methyltransferase (COMT) was discovered in
1957 by the Nobel Prize Winner biochemist Julius Axelrod.
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COMT is an extra cellular enzyme that breaks down DA,
adrenaline, and noradrenaline in the synapse. COMT is in-
volved in the metabolism of the catecholamine neurotransmit-
ters (DA, epinephrine, and norepinephrine). The enzyme in-
troduces a methyl group donated by SA-denosyl-methionine
to the catecholamine. Any compound having a catechol struc-
ture, like catechol-estrogens and catechol-containing flavo-
noids, are substrates of COMT, for example, L-dopa, a precur-
sor of catecholamines and an important substrate of COMT.
Variability of the COMT activity has previously been associ-
ated with the Val158Met polymorphism of the COMT gene
and alcoholism. Serý et al. [37] found an association between
alcoholism in male subjects and the Val158Met polymor-
phism of the COMT gene. Serý et al. also found the significant
difference between allele and genotype frequencies of male
alcoholics and male controls. In one of the subjects genotyped
with heroin addiction, carries of the DRD2 A1 allele, also
carried the low enzyme COMT activity genotype (A/A). This
is in agreement with the work of Cao et al. [38] in 2003 who
found no association with the high G/G and heroin addiction.
No significant differences in genotype and allele frequencies
of 108 val/met polymorphism of COMT gene were observed
between heroin-dependent subjects and normal controls. No
differences in genotype and allele frequencies of 900 Ins
C/Del C polymorphism of COMT gene were observed be-
tween heroin-dependent subjects and normal controls. While
there is still some controversy regarding the COMT associa-
tion with heroin addiction, it was also interesting that the A
allele of the val/met polymorphisms (−287A/G) found byCao
et al. [38] was found to be much higher in heroin addicts than
controls. Faster metabolism results in reduced DA availability
at the synapse, which reduces postsynaptic activation, induc-
ing hypodopaminergic functioning. Generally, Vandenbergh
et al. [39] in 1997, and others [40] supported an association
with the Val allele and Substance Use Disorder, but others did
not [41]. Li et al. [42] found the COMT rs737866 gene
variants were independently associated with both novelty
seeking (NS) and age of onset of drug use. Those subjects
with the TT genotype had higher NS subscale scores and an
earlier onset age of heroin use than individuals with CTor CC
genotypes. In a multivariate analysis, the inclusion of the NS
sub score variable weakened the relationship between the
COMT rs737866 TT genotype and an earlier age of onset of
drug use. Li’s findings that COMT is associated with both NS
personality traits and with the age of onset of heroin use helps
to clarify the complex relationship between genetic and psy-
chological factors in the development of substance abuse.
Case-control analyses did not show any significant difference
in allele or genotype distributions. However, a dimensional
approach revealed a significant association between the
COMT-Val (158) Met and NS. Both controls and opiate users
with Met/Met genotypes showed higher NS scores compared
to those with the Val allele. Demetrovics et al. [43] reported
the NS scores also were significantly higher among opiate
users; however, no interaction was found between group
status and COMT genotype. A functional single nucleotide
polymorphism (a common normal variant) of the gene for
COMT has been shown to affect cognitive tasks broadly
related to executive function, such asset shifting, response
inhibition, abstract thought, and the acquisition of rule sorting
structure. This polymorphism in the COMT gene results in the
substitution of the amino acid valine for methionine. It has
been shown that this valine variant catabolizes DA at up to
four times the rate of its methionine counterpart resulting in a
significant reduction of synaptic DA following neurotransmit-
ter release, ultimately reducing dopaminergic stimulation of
the post-synaptic neuron [44] another driver in the GARS.
Monoamine Oxidase-A
Monoamine oxidase-A (MAOA) is an enzyme that degrades
the neurotransmitters 5-HT, norepinephrine, and DA in the
mitochondria. MAOA is involved with both physical and
psychological functioning and classified as a flavoprotein
since it contains the covalently bonded cofactor FAD. MAOA
is an oxidative catalyst that uses oxygen to deaminate-remove
an amine group from molecules, resulting in the correspond-
ing aldehyde and ammonia.
Both forms of MOA (A and B) enzymes are substrates for
the activity of a number of monoamine oxidase inhibitor drugs
and are, therefore, well known in pharmacology. They are
particularly important in the catabolism of monoamines
ingested in food and vital to the inactivation of monoaminer-
gic neurotransmitters. They display different specificities
MAO-A primarily breaks down serotonin, melatonin, norepi-
nephrine, and epinephrine while phenylalanine and benzyl
amine are mainly broken down byMAO-B. Both forms break
down DA, tyramine and tryptamine equally.
The gene that encodes MAOA is found on the X chromo-
some is located 1.2 kb upstream of the MAOA coding se-
quences and contains a polymorphism (MAOA-uVNTR)
[45]. The MAOA-uVNTR consists of a 30-base pair repeated
sequence, six allele variants containing either 2-, 3-, 3.5-, 4-,
5-, or 6-repeat copies [46]. Functional studies have indicated
the alleles confer variations in transcriptional efficiency, for
example, the 3.5- and 4-repeat alleles result in higher efficien-
cy, whereas, the 3-repeat variant conveys lower efficiency
[47]. To date, there are fewer consensuses regarding the tran-
scriptional efficiency of the other less commonly occurring
alleles, for example, 2-, 5-, and 6-repeat. TheMAOA gene is a
highly plausible candidate for effecting differences in the
manifestation of psychological traits and psychiatric disorders
based on its primary role in regulating monoamine turnover,
and thereby influencing levels of norepinephrine, DA, and 5-
HT [48]. Levels of MAO-A in the brain of patients with major
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depressive disorder, measured using positron emission tomog-
raphy (PET), are elevated by an average of 34 %. Recently,
evidence has indicated that the MAOA gene may associate
with depression [49] and stress [50]. Evidence regarding
whether lower or higher transcriptional efficiency of the
MAOA gene, is positively associated with psychological pa-
thology, has however, been mixed. The MAOA-uVNTR
polymorphism low-activity 3-repeat allele has been positively
related to symptoms of cluster B personality disorders and
antisocial personality [51]. Other studies suggest that un-
healthy psychological characteristics such as trait aggressive-
ness and impulsivity are related to alleles associated with
higher transcriptional efficiency. Low MAO activity and the
neurotransmitter DA are both important factors in the devel-
opment of alcohol dependence. Huang et al. [52] investigated
whether the association between the DRD2 gene and alcohol-
ism is affected by different polymorphisms of the MAO type
A (MAOA) gene since MAO is an important enzyme associ-
ated with the metabolism of biogenic amines. They found that
the genetic variant of the DRD2 gene associated with the
anxiety, depression (ANX/DEP) alcoholic phenotype, and
the genetic variant of the MAOA gene was associated with
alcoholism. Specifically, subjects carrying the MAOA 3-
repeat allele and genotype A1/A1 of the DRD2 were 3.48
times more likely to be ANX/DEP alcoholics than the subjects
carrying the MAOA 3-repeat allele and DRD2 A2/A2 geno-
type. Thus, the MAOA gene may modify the association
between the DRD2 gene and ANX/DEP alcoholic phenotype.
Overall, Vanyukov et al. [53] suggested that, although not
definitive, variants in MAOA account for a small portion of
the variance of risk for Substance Use Disorder, possibly
mediated by liability to early onset behavioral problems.
Dopamine D1 Receptor Gene
The DA receptor D1, also known as DRD1 a subtype of the
DA receptor is a protein encoded by the DRD1 gene and the
most abundant DA receptor in the human central nervous
system where it expresses primarily in the caudate putamen.
This G-protein-coupled receptor activates cyclic AMP-
dependent protein kinases and stimulates adenylyl cyclase.
D1 receptors regulate neuronal growth and development,
modulate DA D2 receptor-mediated events and mediate some
behavioral responses. There are two transcript variants of the
DRD1 gene that are initiated at alternate transcription sites.
The DA D1 receptor has been associated with many brain
functions that include, motor control, inattentive symptoms,
and reward and reinforcement mechanisms. Betel et al. [54]
found that the DRD1 gene polymorphism Tallele of the rs686
was significantly (P=0.0008) more frequent in patients with
alcohol dependence. Frequency increased with severe depen-
dence and was even higher for patients with severe
complications like withdrawal seizures. Alcohol dependence
was significantly, more precisely associated with a specific
haplotype rs686*T-rs4532*G within the DRD1 gene. In an-
other study, Kim et al. [55] found that the severity of the
alcohol-related problem as measured by the Alcohol Use
Disorders Identification Test in a gene dose-dependent man-
ner, was significantly associated with one 5′ UTR polymor-
phism in the DRD1 (DRD1-48A>G) gene; 24.37 (±8.19)
among patients with −48A/A genotype, 22.37 (±9.49) among
those with −48A/G genotype, and 17.38 (±8.28) among those
with −48G/G genotype (P=0.002). Novelty seeking, harm
avoidance and persistence were also found to be associated
with the DRD1-48A>A genotype. Most recently, Peng et al.
[56] indicated that DRD1 gene polymorphism may be asso-
ciated with the rapid acquisition of heroin dependence, from
first drug use but may not play an important role in the
susceptibility to heroin dependence in the Chinese Han pop-
ulation. Others have also found significant associations with
opiate abuse relative to controls [57]. DRD1 antagonists may
indeed reduce the acquisition of cocaine-cue associations and
cocaine-seeking behavior. Genetic association studies re-
vealed that polymorphisms of the DRD1 gene significantly
associated with nicotine dependence [58]. Ni et al. [59] found
a significant association between DRD1 and bipolar disorder
for haplotype TDTanalysis. Thus, these results suggest DRD1
may play a role in the etiology of bipolar disorder.
Dopamine D2 Receptor Gene (DRD2)
DA receptor D2, also known as DRD2, is a protein that is
encoded by the DRD2 gene which encodes the D2 subtype of
the DA receptor in humans. This G protein-coupled receptor
inhibits adenyl cyclase activity. Two transcript variants encode
different isoforms and a third variant that has been described
are the result of alternative splicing of the gene. In mice, of
D2R surface expression is regulated in the dentate gyrus by
the calcium sensor NCS-1 and controls exploration, synaptic
plasticity, and memory formation.
DA has the chemical formula (C6H3 (OH)2-CH2-CH2-
NH2) is a member of the catecholamine family. DA is a
precursor to the chemical messengers’ epinephrine
(adrenaline) and norepinephrine (noradrenaline). Arvid Carls-
son won a share of the 2000 Nobel Prize in Physiology and
Medicine for showing that DA is not just a precursor to these
substances, but is also a neurotransmitter.
Older antipsychotic drugs, like haloperidol and chlorprom-
azine are DRD2 antagonists, however they are exceedingly
nonselective, being selective for the “D2-like family” recep-
tors; binding to D2, D3, and D4 and many other receptors,
such as, those for 5-HT and histamine. This lack of selectivity
makes them difficult to research and results in a range of side
effects. Similarly, older DA agonists like bromocriptine and
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cabergoline used to treat Parkinson’s disease are also poorly
selective. However, the number of selective D2 ligands avail-
able for scientific research is likely to increase.
Almost a decade before Carlsson and others were awarded
the Nobel Prize the DA D2 receptor gene (DRD2) was first
associated with severe alcoholism and is today the most
widely studied gene in psychiatric genetics [7]. The Taq1 A
is a SNP (rs: 1800497) originally thought to be located in the
3′-untranslated region of the DRD2 but has since been shown
to be located within exon 8 of an adjacent gene, the ankyrin
repeat and kinase domain containing 1 (ANKK1). Important-
ly, while there may be distinct differences in function, the
miss-location of the Taq1A allele may be attributable to the
ANKKI and the DRD2 being on the same haplotype or the
ANKKI being involved in reward processing through a signal
transduction pathway [60]. The ANKKI and the DRD2 gene
polymorphisms may have distinct and different actions with
regard to brain function [61]. Presence of the A1+ genotype
(A1/A1, A1/A2) compared to the A− genotype (A2/A2) is
associated with reduced receptor density [62–64]. This
reduction causes hypodopaminergic functioning in the
DA reward pathway. Other DRD2 polymorphisms such
as the C (57T, A SNP (rs: 6277)) at exon 7 also associates
with a number of RDS behaviors including drug use [65].
Compared to the T− genotype (C/C), the T+ genotype
(T/T, T/C) is associated with reduced translation of
DRD2 mRNA and diminished DRD2 mRNA, leading to
reduced DRD2 density and a predisposition to alcohol
dependence [66]. The Taq1 A allele is a predictive risk
allele in families [67].
More recently, Kraschewski and colleagues [68] found
the DRD2 haplotypes I-C-G-A2 and I-C-A-A1 to occur
with a higher frequency in alcoholics. The rare haplotype
I-C-A-A2 occurred less often in alcoholics and was less
often transmitted from parents to their affected children (1
vs. 7). Among the subgroups, I-C-G-A2 and I-C-A-A1
had a higher frequency in Cloninger 1 alcoholics and
alcoholics with a positive family history. Cloninger 2
alcoholics had a higher frequency of the rare haplotype
D-T-A-A2 as compared with controls. In patients with a
positive family history, haplotype I-C-A-A2 and
Cloninger 1 alcoholics, haplotype I-T-A-A1 was less often
present, confirming that haplotypes, which are supposed
to induce a low DRD2 expression, were associated with
alcohol dependence. Furthermore, supposedly high-
expressing haplotypes weakened or neutralized the action
of low-expressing haplotypes [68]. Moreover, Kazantseva
et al. [69] found, significant effects of the ANKK1/DRD2
Taq1A on “Neuroticism” and of SLC6A3 rs27072 on
“Persistence” in both genders. The association between
ANKK1/DRD2 Taq1A A2/A2-genotype and higher Nov-
elty Seeking and lower Reward Dependence was shown
in men but not in women.
Dopamine D3 Receptor Gene
The DA D3 receptor is a protein that is encoded by the DRD3
gene in humans and is a subtype of the DA receptor which
inhibits adenylyl cyclase through inhibitory G-proteins. This
receptor is expressed in older regions of the brain phylogenet-
ically. This suggests that it is important in emotional functions.
It is a target for drugs that treat Parkinson’s disease, schizo-
phrenia, and drug addiction. Differently encoded isoforms
from alternative gene splicing result in transcription of multi-
ple variants. Some of these variants may be subject to
nonsense-mediated decay, however, in rodent models of de-
pression D3 agonists like pramipexole, rotigotine, and 7-OH
DPAT, among others, display antidepressant effects.
Data from Vengeliene et al. [70] revealed an up-regulation
of the DA D3 receptor (D3R) in the striatum after 1 year of
voluntary alcohol consumption of alcohol preferring rats that
was confirmed by qRT-polymerase chain reaction. This find-
ing was further supported by up-regulation of striatal D3R
mRNA found in non-selected Wistar rats, after long-term
alcohol consumption when compared with age-matched con-
trol animals. Moreover, they examined the role of the D3R in
mediating alcohol relapse behavior. They used the alcohol-
deprivation-effect model, in long-term alcohol drinking
Wistar rats and the model of cue-induced reinstatement of
alcohol-seeking behavior, using the selective D3R antagonist
SB-277011-A (0, 1, 3, and 10 mg/kg) and the partial agonist
BP 897 (0, 0.1, 1, and 3 mg/kg). Both treatments caused a
dose-dependent reduction of relapse-like drinking in the
alcohol-deprivation-effect model, as well as a decrease in
cue-induced ethanol-seeking behavior. They concluded that
long-term alcohol consumption led to an up-regulation of the
DA D3R that might have contributed to alcohol-seeking and
relapse. Moreover, the Gly9, Gly9 genotype of the DRD3
Ser9Gly polymorphism was associated with increased rates
of obsessive personality disorder symptomatology [71].
Furthermore, several lines of evidence indicate that dopa-
minergic neurotransmission is involved in the regulation of
impulsive aggression and violence and that genetically deter-
mined variability in dopaminergic gene expression modifies
complex traits including that of impulsivity and aggression. In
one study, Retz et al. [72] reported an association of the DRD3
polymorphism with impulsiveness according to Eysenck’s
EIQ and scores on the German short version of the Wender
Utah Rating Scale (WURS-k), which they used for the assess-
ment of a history of attention deficit hyperactivity disorder
(ADHD) symptoms. This association was detected in a group
of violent offenders, but not in non-violent individuals.
Highest scores of EIQ impulsiveness and the WURS-k were
found in heterozygous violent individuals while homozygotes
showed significant lower rating scores, suggesting a heterosis
effect. The results of their study suggest that variations of the
DRD3 gene are likely involved in the regulation of
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impulsivity and some psychopathological aspects of ADHD
related to violent behavior.
Finally, as opiates increase DA transmission, Spangler
et al. [73] measured the effects of morphine on DA-related
genes using a real-time optic PCR assay that reliably detects
small differences in mRNA in discrete brain regions. As
reported previously by others, there was no alteration in
D1R mRNA and a 25 % decrease in D2R mRNA in the
caudate-putamen, 2 h after the final morphine injection. Im-
portantly, in the same RNA extracts, D3R mRNA showed
significant increases of 85 % in the caudate-putamen and
165 % in the ventral midbrain, including the substantia nigra
and VTA. There were no other significant morphine effects.
The understanding of the ability of D3R agonists to reduce the
effects of morphine was extended by the finding that chronic
intermittent injections of morphine caused an increase in D3R
mRNA extends.
Dopamine D4 Receptor Gene
The DA receptor D4 is encoded by the DRD4 gene on
chromosome 11 located in 11p15.5 in humans. Like the
DRD2 the D4 receptor is a G protein-coupled receptor, acti-
vated by the neurotransmitter DA. It also inhibits the adenyl-
ate cyclase enzyme which reduces the intracellular second
messenger cyclic AMP concentration. The DRD4 has been
associated with numerous psychiatric and neurological condi-
tions including addictive behaviors, and eating disorders (like
binge-eating anorexia and bulimia nervosa, bipolar disorder)
schizophrenia and Parkinson’s disease. Slight variations (mu-
tations/polymorphisms) in the human DRD4 gene include: A
48-base pair VNTR in exon 3; 13-base pair deletion of bases
235 to 247 in exon 1; C-521T in the promoter; Val194gLY; 12
base pair repeat in exon I; A polymorphic tandem duplication
of 120 bp. These mutations have been associated with a
number of behavioral phenotypes, including autonomic ner-
vous system dysfunction, ADHD, schizophrenia, and the
personality trait of novelty seeking. Specifically, the 48-base
pair VNTR in exon 3 ranges from 2 to 11 repeats. Polymor-
phisms with 6 to 10 repeats are the “Long” versions of the
alleles. The frequency of the alleles varies considerably be-
tween populations, for example, the incidence of the 7-repeat
version is high in America and low in Asia. The DRD4 long
variant, or more specifically the 7 repeat (7R), has been
loosely linked to psychological traits and disorders like sus-
ceptibility for developingADHD appears to react less strongly
to DA molecules. The 7R allele appears to have been selected
about 40,000 years ago then in 1999, Chen et al. [74, 75]
showed that nomadic populations had higher frequencies of
7R alleles than sedentary ones. They also observed that higher
frequency of 7R/long alleles in populations who migrated
further from 1,000 to 30,000 years ago. Recently, it was found
that Ariaals with the 7R alleles, who are newly sedentary
(non-nomadic), are not as healthy as nomadic Ariaal men with
7R alleles [76].
Despite early findings of an association between the DRD4
48 bp VNTR and novelty seeking (characteristic of explor-
atory and excitable people), a 2008 meta-analysis compared
36 published studies of novelty seeking and the polymor-
phism and found no effect. The meta-analysis of 11 studies
did find that another polymorphism in the gene, the −521C/T,
showed an association with novelty seeking [77]. In any case,
novelty-seeking behavior probably is mediated by several
genes, and the variance attributable to DRD4 by itself is not
particularly large.
Several studies have suggested that parenting may affect
the cognitive development of children with the 7-repeat allele
of DRD4 [78]. Parenting that has maternal sensitivity, mind-
fulness, and autonomy-support at 15 months was found to
alter children’s executive functions at 18 to 20 months [78].
Children with poorer quality parenting were more impulsive
and sensation seeking than those with higher quality parenting
[78]. Higher quality parenting was associated with better
effortful control in 4-year-olds [78] and these effects are
impacted by epigenetic markers on chromatin structures.
There is evidence that the length of the D4 DA receptor
(DRD4) exon 3 variable number of tandem repeats (VNTR)
affects DRD4 functioning by modulating the expression and
efficiency of maturation of the receptor [79]. The 7R VNTR
requires significantly higher amounts of DA to produce a
response of the same magnitude as other size VNTRs [80],
and this reduced sensitivity or DA resistance leads to
hypodopaminergic functioning. Thus, 7R VNTR has been
associated with substance-seeking behaviors [81, 82]. How-
ever, not all reports support this association. Biederman et al.
[83] evaluating a number of putative risk alleles using survival
analysis, revealed that by 25 years of age, 76 % of subjects
with a DRD4 7R allele were estimated to have significantly
more persistent ADHD compared with 66 % of subjects
without the risk allele. In contrast, there were no significant
associations between the course of ADHD and the DAT1 10-
repeat allele and 5HTTLPR long allele. These findings sug-
gested that the DRD4 7R allele, is associated with increased
persistence in the course of ADHD. Moreover, Grzywacz
et al. [84] evaluated the role of DRD4 exon 3 polymorphisms
(48 bp VNTR) in the pathogenesis of alcoholism and found
significant differences in the short alleles (2–5 VNTR) fre-
quencies, between controls and patients with a history of
delirium tremens and/or alcohol seizures. A trend also was
observed in the higher frequency of short alleles amongst
individuals with an early age of onset of alcoholism. The
results of this study suggest that inherited short variants of
DRD4 alleles (3R) may play a role in the pathogenesis of
alcohol dependence and carriers of the 4R may have a protec-
tive effect for alcoholism risk behaviors. It is of further interest
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that work from Kotler et al. [85] in heroin addicts illustrated
that central dopaminergic pathways figure prominently in
drug-mediated reinforcement including novelty seeking, sug-
gesting that DA receptors are likely candidates for association
with substance abuse. These researchers showed that the 7R
allele was significantly over-represented in the opioid-
dependent cohort and conferred a relative risk of 2.46.
Dopamine Transporter Gene (DAT1)
The DA transporter, also known as DA active transporter
(DAT, SLC6A3), moves DA the neurotransmitter out of the
synapse back into the cytosol via a membrane-spanning pro-
tein pump. From there, DA and norepinephrine are seques-
tered by other transporters into vesicles for later storage and
release. DA reuptake through which DA is cleared from
synapses primary by the mechanism of the DAT gene, al-
though in the prefrontal cortex, there may be an exception,
where evidence points to a larger role for the norepinephrine
transporter [86, 87].
DAT is thought to be implicated in a number of DA-related
disorders, including ADHD, bipolar disorder, clinical depres-
sion, and RDS. The gene that encodes the DAT protein is
located on human chromosome 5, consists of 15 coding exons
and is roughly 64 kbp long. Evidence for the associations
between DAT- and DA-related disorders has come from a
type of genetic polymorphism, known as a VNTR, in the
DAT gene (DAT1), which influences the amount of protein
expressed. DAT is an integral membrane protein that removes
DA from the synaptic cleft and deposits it into surrounding
cells, thus terminating the signal of the neurotransmitter. DA
underlies several aspects of cognition, including reward, and
DAT facilitates regulation of that signal [88, 89].
In the model for monoamine transporter function that is
most widely accepted, before DA can bind sodium ions must
bind to the DAT extracellular domain. Once DA binds to
sodium ions change in the conformation of the protein allows
both the DA and the sodium to unbind intracellularly [90].
Studies using electrophysiology and radioactive-labeled DA
have confirmed that DA is transported across the neuronal
membrane with sodium ions. The chlorine ions are required to
prevent a buildup of positive charge. These studies have
demonstrated that the direction and rate of transport, depends
on the sodium gradient [77]. It is known that any resultant
activity changes in membrane polarity will profoundly affect
transport rates and depolarization will induce DA release [91].
Like the GABA transporter, the brain distribution of DAT
is highest in the nigrostriatal, mesocortical, and mesolimbic
pathways [92] and gene expression patterns in adult mouse
show that expression is high in the substantia nigra pars
compacta [93]. It has been confirmed that DAT in the
mesocortical pathway was also found in the VTA. DAT is
localized in the axon terminals of the striatum and shown
experimentally to be co-localized with nigrostriatal terminals,
tyrosine, and DA D2 receptors. These results suggest that
striatal DA reuptake may occur and DA diffuses into the
substantia nigra from the synaptic cleft. It appears that DAT
is transported into the dendrites, where it can be found in pre-
and postsynaptic active zones, smooth endoplasmic reticulum,
and plasma membrane. These localizations suggest that intra-
cellular and extracellular DA levels of nigral dendrites are
modulated by DAT.
Genetics and Regulation
The gene for DAT is located on chromosome 5p15, it is
confirmed that the protein encoding for the gene is over
64 kb long and comprises 15 coding segments or exons
[94]. The DAT gene has a VNTR at the intron 8 region and
another at the 3′ end (rs28363170) [95]. VNTR differences
have been shown to influence the basal level of expression of
the transporter and associate with RDS behaviors, such as
various addictions and other DA-related disorders [96]. Inter-
estingly, Nurri, a nuclear receptor that regulates many DA-
related genes, can bind the promoter region of this gene and
subsequently induce expression [97]. In addition, the DAT
promoter also may be the target of the transcription factor Sp-
1. Kinases are essential for functional regulation of this pro-
tein. The rate at which DAT removes DA from the synapse
affecting the quantitative amount of DA in the cell depends
upon kinases. Understanding the molecular neurobiology of
the DAT gene provides the basis for studies showing hyper-
activity, severe cognitive deficits, and motor abnormalities of
mice with noDA transporters [98]. Similarities of these effects
to the symptoms of ADHD characteristics are striking. Dif-
ferences in the functional differences, in VNTR, have been
identified as risk factors for bipolar disorder [99] and ADHD
[100]. Although controversial, data have emerged that suggest
there also is an association with stronger alcohol withdrawal
symptoms [101, 102]. On the other hand, non-smoking be-
havior and ease of quitting is associated with an allele of the
DAT gene of the with normal protein levels [103]. Addition-
ally, male adolescents in high-risk families, with an absence of
maternal affection and a disengagedmother, who carry the 10-
allele VNTR repeat, associate with a statistically significant
affinity for antisocial peers [104]. Increased DAT activity is
associated with clinical depression [105]. Decreased DAT
levels of expression are associated with aging, and may un-
derlie a mechanism that compensates for decreases in DA
release as a person ages [106].
Cocaine reduces the rate of transport, blocking DAT by
binding directly to the transporter [107]. In contrast, amphet-
amines trigger a signal cascade thought to involve PKC or
MAPK that leads to the internalization of DAT molecules,
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which are normally expressed on the neuron’s surface [108].
Amphetamine on DAT also has a direct effect in the increased
levels of secreted DA [109]. Lipophilic AMPH diffuses into
the cytoplasm and the DA secretory vesicles disrupting the
proton gradient established across the vesicle wall. This in-
duces a leaky channel, and DA diffuses out into the cyto-
plasm. Additionally, AMPH causes a reversal of normal DA
flow at the DAT. Instead of DA reuptake, in the presence of
AMPH, a reversal in themechanism of DAToccurs causing an
outflow of DA released into the cytoplasm into the synaptic
space changing it from a symporter to an antiporter-like func-
tionality [110–112]. These mechanisms both result in less
removal of DA from the synapse, increased signaling, which
may underlie the pleasurable feelings elicited by these sub-
stances [113].
The DA transporter protein regulates DA-mediated neuro-
transmission by rapidly accumulating DA that has been re-
leased into the synapse [113]. Moreover, within 3 noncoding
region of DAT1 lies a VNTR polymorphism [113]. There are
two important alleles that may independently increase risk for
RDS behaviors. The 9 repeat (9R) VNTR has been shown to
influence gene expression and to augment transcription of the
DA transporter protein [114]. Therefore, this results in an
enhanced clearance of synaptic DA, yielding reduced levels
of DA to activate postsynaptic neurons. Presence of the 9R
VNTR has been linked to Substance Use Disorder [115], but
not consistently [116]. Moreover, in terms of RDS behaviors,
Cook et al. [117] was the first group that associated tandem
repeats of the DAT gene in the literature. While there have
been some inconsistencies associated with the earlier results,
the evidence is mounting in favor of the view that the 10R
allele of DAT is associated with high risk for ADHD in
children and adults alike. Specifically, it was the non-
additive association for the 10-repeat allele to be significant
for hyperactivity-impulsivity symptoms, but exploratory anal-
yses of the non-additive association of the 9-repeat allele of
DAT1 with HI and oppositional defiant disorder symptoms
also was significant. However, Volkow’s [118] group found
that 12 months of methylphenidate treatment significantly
increased striatal DA transporter availability in ADHD (cau-
date, putamen, and ventral striatum) by 24 %, whereas there
were no changes in control subjects retested at the 12-month
interval.
Gamma Aminobutyric Acid (GABA) 1519T>CGABA
(A)alpha6Gene
The role of GABA as the primary inhibitory neurotrans-
mitter is the regulation of neuronal excitability through-
out human central nervous system. First synthesized in
1883, as a plant and microbe metabolic product, it was
not until 1950 that GABA was found to be an integral to
brain functioning and directly responsible for muscle
tone regulation [119].
GABA acts at the brains inhibitory synapses where it binds
to specific transmembrane receptors. This binding in the plas-
mamembrane of both pre- and postsynaptic neuronal process-
es opens the ion channels, discovered by Nobel Prize winner
Erwin Neher in 1991. Ion channels allow chloride ions which
are negatively charged into the cell or potassium ions which
are positively charged to flow out of the cell. These actions
change the transmembrane potential, causing hypo- or hyper-
polarization. Polarization depends on the direction chloride
flow. GABA is depolarizing (excitatory) when net chloride
flows out of the cell and hyperpolarizing (inhibitory) when the
net chloride flows into the cell. It is known that as the brain
develops into adulthood the role of GABA changes from
excitatory to inhibitory [120].
There are two known classes of GABA receptor: GABAA
receptor, which is part, of a ligand-gated ion complex, and
GABAB (G protein-coupled) metabotropic receptors that use
intermediaries to open or close ion channels. GABAergic
neurons that produce GABA have a mostly inhibitory action
at receptors, although some GABAergic neurons, such as
chandelier cells are able to excite their glutamatergic receptors
or neurons counterparts [120–123].
In the metabolic pathway, called the GABA shunt, the
enzyme L-glutamic acid decarboxylase and pyridoxal phos-
phate, the active form of vitamin B6, is used, as a cofactor, to
synthesize GABA in the brain from glutamate, the principal
excitatory neurotransmitter. In this process that converts glu-
tamate into GABA [124, 125], the GABA transaminase en-
zyme catalyzes the conversion of 2-oxoglutarate and 4-
aminobutanoic acid into glutamate and succinic semialde-
hyde. Then the enzyme succinic semialdehyde dehydrogenase
oxidizes succinic semialdehyde into succinic acid which en-
ters the citric acid cycle as a usable source of energy [126].
Drugs, known as GABA analogues or GABAergic drugs
act as allosteric modulators of GABA receptors, to increase
the amount of available GABA and usually have, anti-anxiety,
anti-convulsive, and relaxing effects [127, 128]. In general,
GABA does not cross the blood-brain barrier [129]. At least
one study suggests that blocking GABA increases the amount
of DA released [130].
Genetics of GABA Receptor Gene Polymorphisms
GABA receptor genes have received some attention as candi-
dates for drug use disorders. One reason for this is that the DA
and GABA systems are functionally interrelated [112]. Re-
search suggests that DA neurons projecting from the anterior
VTA to the NAc are tonically inhibited by GABA through its
actions at the GABAA receptor [131]. Moreover, it has been
shown that alcohol [132] or opioids [133] enhancement of
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GABAergic (through GABAA receptor) transmission inhibits
the release of DA in the mesocorticolimbic system. Thus, a
hyperactive GABA system, by inhibiting DA release, could
also lead to hypodopaminergic functioning. Because of this,
GABA genes are of interest in the search for causes of drug
use disorders. A dinucleotide repeat polymorphism of the
GABA receptor β3 subunit gene (GABRB3) results in either
the presence of the 181-bp G1 or 11 other repeats designated
as non-G1 (NG1) [134]. Research indicates that the NG1 has
an increased prevalence in children of alcoholics [134]. Pres-
ence of the NG1 has been associated with alcohol dependence
[135, 136]. In addition, other GABA receptor genes have been
associated with this disorder [137]. In fact, craving for alcohol
and food has been studied in association with alcohol depen-
dence and eating disorders, respectively. Thus, one subclass of
the GABA receptor, 1519T>C GABA (A) alpha 6 has been
associated with both ethanol dependence and weight gain.
This gene polymorphism has been associated with
hypo-cortisolism and perhaps abdominal obesity. Inter-
estingly, the pathophysiology may involve various epige-
netic factors, such as stress that destabilize the GABA-
hypothalamic-pituitary adrenal systems in those with ge-
netic vulnerability. In T-allele carriers, the change in
craving for alcohol during treatment for alcohol depen-
dence is negatively associated with changes in craving
for food as well [137].
Expression patterns of GABAergic genes in rodent brains
have been elucidated but not in humans. There are many
GABAergic pathways and factor analysis involving global
expression on 21 of these pathways has been performed.
Specifically, postmortem data from hippocampus of eight
alcoholics, eight cocaine addicts, and eight controls was eval-
uated to determine factor specificity for response to chronic
alcohol/cocaine exposure. While RNA-Seq six gene expres-
sion factors were identified and loaded onto two factors, most
genes loaded (≥0.5) onto one factor. These analyses led to the
understanding that the chromosome 5 gene cluster was the
largest factor (0.30 variance) and as such encodes the most
common GABAA receptor, α1β2γ2, and genes encoding the
α3β3γ2 receptor. Interestingly, within this factor, these genes
were unresponsive to chronic alcohol/cocaine exposure. How-
ever, chronic alcohol/cocaine exposure affected chromosome
4 gene-cluster factor (0.14 variance) that encoded theα2β1γ1
receptor. Moreover, in both alcoholics and cocaine-dependent
humans, two other factors (0.17 and 0.06 variance) included
genes specifically involved in GABA synthesis and
Table 3 Four major subtypes of
opiate receptors
a The name is based on order of
discovery (from Wikipedia)
Receptor Subtypes Location Function
delta (δ)
DOP
OP1
(I)
δ1, δ2 • Brain
▪ Pontine nuclei
▪ Amygdala
▪ Olfactory bulbs
▪ Deep cortex
• Peripheral sensory neurons
Analgesia
Antidepressant effects
Convulsant effects
Physical dependence
Perhaps of mu-opioid
receptor-mediated respiratory
depression
kappa (κ)
KOP
OP2
(I)
κ1, κ2, κ3 Brain
• Hypothalamus
• Periaqueductal gray
• Claustrum
Spinal cord
• Substantia gelatinos
• Peripheral sensory neurons
Analgesia
Anticonvulsant effects
Dissociative and delirium effects
Diuresis
Dysphoria
Miosis
Neuroprotection
Sedation
mu (μ)
MOP
OP3
(I)
μ1, μ2, μ3 Brain
• Cortex (laminae III and IV)
• Thalamus
• Striosomes
• Periaqueductal gray
• Rostral ventromedial medulla
Spinal cord
• Substantia gelatinosa
• Peripheral sensory neurons
• Intestinal tract
μ1:
• Analgesia
• Physical dependence
μ2:
• Respiratory depression
• Miosis
• Euphoria
• Reduced GI motility
• Physical dependence
μ3:
• Possible vasodilation
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synaptic transport showed expression changes. It has
been suggested that there is specificity of GABAergic
gene groups, for response to chronic alcohol/cocaine
exposure. Thus, understanding the nature of GABAergic
gene group specificity could have therapeutic implica-
tions for combating stress-related craving and relapse
[138].
Mu-Opioid Receptor Genes
Opioid receptors are a group of G-protein coupled receptors
with opioids as ligands [139–141]. The original work on these
receptors occurred in the late 1960s, with the first group being
that of Avram Goldstein at Stanford [142]. The endogenous
opioids are dynorphins, enkephalin, endorphins, endo-
mophins, and nociception. In 1973, Pert and Snyder were
first to publish a detailed binding study of what turned out to
be the mu-opioid receptor using 3H-naloxone [143], although
two other studies followed shortly after [144, 145]. The opioid
receptors are ~40 % identical to somatostatin receptors
(SSTRs). Opiate receptors are found in the spinal cord diges-
tive tract and are distributed widely in the brain. Themu opiate
receptor (OPRM) has high affinity for enkephalin, beta endor-
phins, and morphine.
An International Union of Basic and Clinical Pharmacolo-
gy (IUPHAR) subcommittee has recommended that appro-
priate terminology for the four principal subtypes of
opioid receptors the three classical (μ, δ, κ) receptors,
and the non-classical (nociception) receptor, should be
MOP, DOP, KOP, and NOP, respectively [146–148]
(Table 3).
Genetics of the Mu Opiate Receptor Gene
The activity at the micro-opioid receptor is central to both pain
responses and opioid addiction. The opioidergic hypothesis
suggests variations at the opioid receptor mu 1 (OPRM1) gene
locus associate with opiate addiction. Several SNPs in exon I
contained in the OPRM1 gene, which encodes for mu-opioid
receptor. The polymerase chain reaction-restriction fragment
length polymorphism method was used to genotype SNPs,
A118G (rs 1799971) and C17T (rs 1799972) that have been
associated with substance abuse. For the 118G allele, the
opioid dependents (n=126) had an approximately 2.5-fold
higher frequency of 0.31 (odds ratio 3.501; CI(95 %) 2.212–
5.555; P<0.0001) while the control subjects (n=156) showed
a frequency of 0.12. For the C17T polymorphism, 0.83 seen in
opioid dependents (n=123; odds ratio of 0.555; CI(95 %)
0.264–1.147; P=0.121) versus the controls (n=57) showed
Table 4 Dopamine D2 receptor gene (a sampling)
Polymorphism (s) Study findings References Comments
SNP rs: 1800497 TaqA1 allele associates with sever alcoholism Blum et al. (1990) First study to associate with alcoholism
(called reward gene)
ANKKI -p.Glu713Lys DRD2 Taq1A RFLP is a single nucleotide
polymorphism (SNP) that causes an amino
acid substitution within the 11th ankyrin
repeat of ANKK1
Neville et al. (2004) The ANKKI gene is a reflection of DRD2 A1
allele
SNP rs: 1800497 This SNP has been found to predict future
RDS behaviors as high as 74 %
Blum et al. (1996) Using Bayesian analysis
SNP rs: 1800497 Presence of the A1+ genotype (A1/A1, A1/
A2) compared to the A− genotype (A2/A2),
is associated with reduced density
Noble et al. (1991) This reduction causes hypodopaminergic
functioning in the dopamine reward
pathway
SNP rs: 6277 at exon 7 T+ allele associates with alcohol dependence Hill et al. (2008) Associates with drug seeking behavior and
other RDS behaviors
SNP rs: 1800497 10 year follow up that carriers of the DRD2
A1 allele have a higher rate of mortality
compared to carriers of the A2 allele in
alcohol dependent individuals
Dahlgren et al. (2011) Taq IA1allele and a substantially increased
relapse rate
DRD2-haplotypes I-C-
G-A2 and I-C-A-A1
Confirmed the hypothesis that haplotypes,
which are supposed to induce a low DRD2
expression, are associated with alcohol
dependence
Kraschewski et al.
(2009)
High frequency of haplotype was associated
with Cloninger Type 2 and family history
of alcoholism
SNP rs: 1800497 Genotype analysis showed a significantly
higher frequency for the TaqIA
polymorphism among the addicts (69.9 %)
compared to control subjects (42.6 %;
Fisher’s exact χ(2), P<0.05)
Teh et al. (2012) The addicts had higher scores for novelty
seeking (NS) and harm avoidance (HA)
personality traits
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a frequency of 0.89 for C allele. Thus, a significant association
was observed between the 118G allele, and opioid depen-
dence but no association was found with C17T polymorphism
[149].
The effects of opiate drugs on pain experiences differ in
humans. Recent twin studies documented individual differ-
ences, in several types of pain that are likely to be substantially
determined by genetics. Genetic components to migraine pain
susceptibility are documented in large twin studies, although
in family studies have found substantial genetic heterogeneity
in migraine. Humans μOR densities also differ. Both in vivo
PET radioligand analyses and binding studies to postmortem
brain samples suggest ranges of 30–50 %, or even larger, in
individual differences in human μOR densities. Elucidation of
the genetic basis for these differences based on receptor ex-
pression would advance substantially understanding of indi-
vidual differences in and drug responses and nociceptive
behaviors. The likelihood of high or low levels of expression
in an individual can be predicted by information about μOR
gene polymorphisms and may allow drug treatments to be
individualized. These data could aid in optimization of dose
ranges and selection of analgesic agents. Pain management for
individuals with acute or long-term pain problems could be
improved. These data could also add new therapeutic speci-
ficities and efficacies to this well-established opiate drug class,
still a major weapon for amelioration of pain states [150].
Decreased analgesic effects of opioids are associated with
the SNP 118A>G in the micro-1 opioid receptor gene
(OPRM1) [151]. One recent study shows that postoperative
pain response in heterozygous patients is affected by the
OPRM1 118A>G polymorphism. The efficacy of the analge-
sic therapy for postoperative pain may be impaired compared
to patients with wild-type genes [151]. In another study, Liu
and Wang [152] reported that the allelic frequency of variant
(118G) allele was 39.6 %, and the prevalence of OPRM1-118
AA, AG, and GG genotypes was 31.3 % (n=30), 58.3 % (n=
56), and 10.4 % (n=10), respectively. For all patients, pre-
treatment to post-treatment pain judgments were reduced sig-
nificantly. Patients with AA genotype had a better analgesic
effect than those with G allele variants (AG or GG genotypes).
Table 5 Dopamine D4 receptor gene (a sampling)
Polymorphism(s) Study findings References Comments
DRD4 - The 7 repeat (7R) VNTR The length of the D4 dopamine receptor
(DRD4) exon 3 variable number of tandem
repeats (VNTR) affects DRD4 functioning
by modulating the expression and
efficiency of maturation of the receptor
Van Tol (1998) The 7 repeat (7R) VNTR requires
significantly higher amounts of
dopamine to produce a response of
the same magnitude as other size
VNTRs
120 bp duplication, -616C/G, and
-521C/T
Strong finding of -120 bp duplication allele
frequencies with schizophrenia (P=0.008);
-521 C/T polymorphism is associated with
heroin addiction
Lai et al.(2010) This reduced sensitivity or “dopamine
resistance” leads to
hypodopaminergic functioning. Thus
7RVNTR has been associated with
substance-seeking behavior
DRD4 7-repeat allele A number of putative risk alleles using
survival analysis revealed that by 25 years
of age 76 % of subjects with a DRD4 7-
repeat allele were estimated to have
significantly more persistent ADHD
compared with 66 % of subjects without
the risk allele
Biederman
et al. (2009)
Findings suggest that the DRD4 7-
repeat allele is associated with a more
persistent course of ADHD
7-repeat allele of the dopamine
D(4) receptor gene (DRD4)
Although the association between ADHD and
DRD4 is small, these results suggest that it
is real
Faraone et al.
(2001)
For both the case-control and family-
based studies, the authors found (1)
support for the association between
ADHD and DRD4, (2) no evidence
that this association was accounted
for by any one study, and (3) no
evidence for publication bias
dopamine D4 receptor (DRD4)
exon 3 polymorphisms (48 bp
VNTR)
Found significant differences in the short
alleles (2–5 VNTR) frequencies between
controls and patients with a history of
delirium tremens and/or alcohol seizures
(P=0.043)
Grzywacz et al.
(2008)
A trend was also observed in the higher
frequency of short alleles amongst
individuals with an early age of onset
of alcoholism (P=0.063)
dopamine D4 receptor (DRD4) -7
repeat allele
Show 7-repeat allele is significantly over-
represented in the opioid-dependent cohort
and confers 2.46 RR
Kotler et al.
(1997)
First report of an association between
opioid addiction and a genetic
polymorphism
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Pre- and post-treatment pain judgments for patients with G
allele variants were also reduced significantly. However, for
patients with AA genotype, pre-treatment and post-treatment
pain judgments were especially dramatic. The require-
ment for rescue analgesia also was highest for patients
with G allele variants. Interestingly, Setiawan et al. [153]
found that one etiological pathway to alcoholism may be
influenced by the A118G substitution, for which naltrex-
one pharmacotherapy is effective. Moreover, studies by
Kranzler et al. [154] showed a modest association between
OPRM1 alleles and substance (alcohol, cocaine, or opioid)
dependence.
Finally, we provide a selective sample of the relationship of
certain reward genes and their respective risk alleles (see
Tables 4, 5, 6, 7, 8, 9, 10, 11, and 12).
Genetic Addiction Risk Score Panel
We are proposing a number of well- known risk alleles based
on a plethora of literature based studies. Table 13 represents a
list of each top gene (s) that should drive the risk stratification
of the individual.
Understanding that RDS is a very complex polygenic
disorder, we have carefully considered and chosen the primary
risk alleles based on thousands of support articles in the
literature. We feel confident that GARS will provide a snap-
shot into RDS risk. We are cognizant that this panel may
change over time as new and other gene polymorphisms are
discovered. Moreover, until we can develop a weighted algo-
rithm based on utilization of “super controls” for RDS, we
cannot provide a perfect test.
GWAS vs Candidate Gene Approach Issues
The need for genetic testing as a way of understanding or
pinpointing therapeutic targets is certainly the wave of the
future. Since the earliest study of the DRD2 gene, a remark-
able list of associations with gene polymorphisms has been
elucidated and eventually morphed into in the field, known
today as Psychiatric Genetics. The DSM criteria are not the
only method of diagnosis of psychiatric disorders. We are
proposing that coupling verified standard pencil and paper
tests, like the Addiction Severity Index among others, with
DSM and GARS should enhance the understanding of each
patient presenting for addiction treatment. In fact, it will
remove guessing by providing objective risk stratification, as
well as opportunities for DNA-targeted therapies (personal-
ized addiction medicine). We are beginning to understand the
power of Genome Wide Association (GWAS) [155] and
EWAS studies, especially the epigenetics of gene expression
via mRNA transcription. This knowledge could pave the way
for either nutraceutical nutrigenomic solutions or highly spe-
cific pharmaceuticals, that by targeting select neuronal sites
can reduce toxic side effects. In either case, we strongly
recommend additional studies to provide the recovering addict
with an epigenetic [156–158] tool to activate DA D2
Table 6 Dopamine transporter gene (DAT1)
Polymorphism Study findings References Comments
Localized to chromosome 5p15.3.
Moreover, within 3 noncoding region
of DAT1 lies a VNTR polymorphism -
9 repeat (9R) VNTR
The 9 repeat (9R) VNTR has been shown to
influence gene expression and to augment
transcription of the dopamine transporter
protein
Byerly et
al.
(1993)
Having this variant results in an enhanced
clearance of synaptic dopamine, yielding
reduced levels of dopamine to activate
postsynaptic neurons
9 repeat (9R) VNTR DAT1, genotype 9/9 was associated with early
opiate addiction
Galeeva
et al.
(2002)
The combination of SERT genotype 10/10
with DAT1 genotype 10/10was shown to be
a risk factor of opiate abuse less than
16 years of age
exon 15 rs27072 and VNTR (DAT),
promoter VNTR and rs25531
The haplogenotypes 6-A-10/6-G-10 and 5-G-
9/5-G-9 were more often present in type 2
alcoholics as compared with type 1
alcoholics [odds ratio (OR): 2.8], and
controls (OR: 5.8), respectively
Reese et al.
(2010)
In a typology proposed by Cloninger on the
basis of adoption studies, a subgroup has
been classified as type2 with patients having
high genetic loading for alcoholism, an early
onset of alcoholism, a severe course, and
coexisting psychiatric problems consisting
of aggressive tendencies or criminality
VNTR polymorphism at the dopamine
transporter locus (DAT1) 480-bp
DAT1 allele
Using the haplotype-based haplotype relative
risk (HHRR) method revealed significant
association between ADHD/UADD and the
480-bp DAT1 allele (chi 2 7.51, 1 df, P=
0.006)
Cook et al.
(1995)
While there have been some inconsistencies
associated with the earlier results the
evidence is mounting in favor of the view
that the 10R allele of DAT is associated with
high risk for ADHD in children and in
adults alike
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Table 7 Catechol-O-methyl-transferase (COMT) [a sampling]
Polymorphism(s) Study findings References Comments
COMT Val 158 Met variation and DRD2
Taq1A genotypes
COMT Val158Met and DRD2 Taq1A may
affect the intermediate phenotype of
central dopamine receptor sensitivity
Schellekens
et al.
(2012)
COMT Val158Met and DRD2 Taq1A may
confer their risk of alcohol dependence
through reduced dopamine receptor
sensitivity in the prefrontal cortex and
hindbrain, respectively
The functional polymorphism (COMT
Val108/158Met) affects COMT activity,
with the valine (Val) variant associated
with higher and the methionine (Met)
variant with lower COMT activity
Male alcoholic suicide attempters, compared
to male non-attempters, had the higher
frequency of Met/Met genotype or
Met allele, and significantly (Kruskal-
Wallis ANOVA on ranks and Mann-
Whitney test) higher aggression and
depression scores
Nedic et al.
(2011)
These results confirmed the associations
between Met allele and aggressive
behavior or violent suicide attempts in
various psychiatric diagnoses, and
suggested that Met allele of the COMT
Val108/158 Met might be used as an
independent biomarker of suicidal
behavior across different
psychopathologies
COMT Val(15) Met variation Both controls and opiate users with Met/Met
genotypes showed higher NS scores
compared to those with the Val allele
Demetrovis
et al.
(2010)
Association of the COMT polymorphism
and NS temperament scale has been
shown for heroin-dependent patients and
controls regardless of group status
A functional polymorphism (COMT
Val158Met) resulting in increased enzyme
activity has been associated with
polysubstance abuse and addiction to
heroin and meth-amphetamine
These results suggest a significant
association between COMT Val158Met
polymorphism and susceptibility to
cannabis dependence
Baranse
et al.
(2008)
Cannabis stimulates dopamine release and
activates dopaminergic reward neurons in
central pathways that lead to enhanced
dependence. Catechol-O-methyl
transferase (COMT) inactivates amplified
extraneuronally released dopamine
Table 8 Serotonin transporter gene (a sampling)
Polymorphism(s) Study findings References Comments
Serotonin transporter promoter
polymorphism [5-HT transporter
gene-linked polymorphic region
(5-HTTLPR)]
5-HTTLPR had age-dependent
effects on alcohol, tobacco and
drug use: substance use did not
differ by genotype at age 9, but at
age 15, the participants with the
short (s)/s genotype had higher
tobacco use, and at age 18, they
were more active alcohol, drug
and tobacco users
Merenäkk et al.
(2011)
Results reveal that expression of genetic
vulnerability for substance use in children
and adolescents may depend on age,
gender, interaction of genes, and type of
substance
The short (s), low activity allele of a
polymorphism (5-HTTLPR) in the
serotonin transporter gene (SLC6A4)
has been related to alcohol
dependence.
The 5-HTTLPR short allele
predicted adolescent’s growth
(slope) in alcohol use over time.
Adolescents with the 5-HTTLPR
short allele showed larger increase
in alcohol consumption than those
without the 5-HTTLPR short
allele
van der Zwaluw
et al. (2010)
5-HTTLPR genotype was not related to the
initial level (intercept) of alcohol
consumption
triallelic 5-HTTLPR genotype : SA/SA
and SA/LG compared to LA/LA
triallelic 5-HTTLPR genotype : SA/
SA and SA/LG compared to LA/
LA
Kosek et al.
(2009)
Previously the 5-HTTLPR s-allele has been
associated with higher risk of developing
chronic pain conditions but in this study we
show that the genotype coding for low 5-
HTT expression is associated with a better
analgesic effect of an opioid. The s-allele
has been associated with downregulation of
5-HT1 receptors and we suggest that
individuals with a desensitization of 5-HT1
receptors have an increased analgesic
response to opioids during acute pain
stimuli, but may still be at increased risk of
developing chronic pain conditions.
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receptors while attenuating the anti-reward effects of DA
D1 and possibly D3 receptors, respectively. Finally, we as
neuroscientists should begin to perform studies that control
for possible comorbid medical and psychiatric conditions
in the research (dual diagnosis). This work supports earlier
non-genetic concepts of addiction in psychiatric medicine
[159–163].
We are cognizant that there is controversy related to the
importance of both GWAS and Whole-Exome Sequencing
(WES) and analytical approaches relative to candidate associ-
ation and linkage studies, used to unravel the contribution of
specific genes and associated polymorphisms to addiction
liability. In the late 1980s realizing the complexity of the
problem of both vulnerability and resilience for risk of drug
abuse and other behavioral addictions, we decided to analyze
candidate genes based on a theoretical model developed and
subsequently published, identified as the “Brain Reward Cas-
cade” [1]. Initially our approach utilizing this “blue print of
reward” involved association rather than linkage analysis
because Lander et al. argued against linkage analysis for
complex disorders like drug addiction [8] instead of linkage
analysis as previously accomplished with one gene one dis-
ease (OGOD).
Important advances have been made over the last two
decades concerning “Psychiatric Genetics”. Certainly, sub-
stantial genetic contributions to addiction liability are now
supported by earlier twin studies and more recently linkage,
candidate association and GWAS studies. Animal studies
initially focusing upon genes that targeted mechanism of
action of major drugs of abuse. Many of these studies were
successful in the identification of quantitative trait loci includ-
ing association of chromosomal 9 (DRD2 gene) and ethanol
behavioral responses [164, 165] as well as other reward genes
including serotonin, opioids and GABA [166]. Most of these
and many other studies have identified gene/proteins that
affect responses to drugs of abuse. Parallel to these animal
Table 9 Mu opiate receptor (MOR) [a sampling]
Polymorphism(s) Study findings References Comments
A single nucleotide polymorphism (SNP) in
the human MOR gene (OPRM1 A118G)
has been shown to alter receptor protein
level in preclinical models and smoking
behavior in humans
Independent of session, smokers
homozygous for the wild-type OPRM1 A
allele exhibited significantly higher levels
of MOR BP (ND) than smokers carrying
the G allele in bilateral amygdala, left
thalamus, and left anterior cingulate cortex
Ray et al.
(2011)
Among G allele carriers, the extent of
subjective reward difference (de-
nicotinized versus nicotine cigarette) was
associated significantly with MOR BP
(ND) difference in right amygdala,
caudate, anterior cingulate cortex, and
thalamus
Polymorphism in A118G in exon 1 and
C1031G in intron 2 of the MOR gene
Results showed a significant association for
both A118G and C1031G polymorphisms
and opioid dependence. The G allele is
more common in the heroin-dependent
group (39.5 % and 30.8 % for A118G and
C1031G polymorphisms, respectively)
when compared to the controls (29.4 %
and 21.1 % for A118G and C1031G
polymorphisms, respectively)
Szeto et al.
(2001)
This study suggests that the variant G allele
of both A118G and C1031G
polymorphisms may contribute to the
vulnerability to heroin dependence
A118G single-nucleotide polymorphism
(SNP) in exon 1 of the MOR gene
(OPRM1), which encodes an amino-acid
substitution, is functional and receptors
encoded by the variant 118G allele bind
the endogenous opioid peptide beta-
endorphin with three-fold greater affinity
than prototype receptors. Other groups
subsequently reported that this variant
alters stress-responsivity in normal
volunteers and also increases the
therapeutic response to naltrexone (a mu-
preferring opioid antagonist) in the
treatment of alcohol dependence
There was a significant overall association
between genotypes with an 118G allele
and alcohol dependence (P=0.0074). The
attributable risk for alcohol dependence in
subjects with an 118G allele was 11.1 %
Bart et al.
(2005)
There was no difference in A118G genotype
between type 1 and type 2 alcoholics. In
central Sweden, the functional variant
118G allele in exon 1 of OPRM1 is
associated with an increased attributable
risk for alcohol dependence
MOR gene knockout (KO) were examined in
wild-type (+/+), heterozygote MOR KO
(+/−) and homozygote MOR KO (−/−)
mice on voluntary ethanol consumption
Heterozygous and homozygous MOR KO
mice consumed less ethanol than wild-
type mice. These effects appeared to be
greater in female KO mice than in male
KO mice. MOR KO mice, especially
females, exhibited less ethanol reward in a
conditioned place preference paradigm
Hall et al.
(2001)
These data fit with the reported therapeutic
efficacy of MOR antagonists in the
treatment of human alcoholism. Allelic
variants that confer differing levels of
MOR expression could provide different
degrees of risk for alcoholism
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studies, human genetic research has evolved over the last
5 years. Now, it is possible to detect genetic variation in the
human genome inexpensively. The era of genome sequencing
began with the detection of SNPs on gene chips. Very recently,
we are also utilizing WES, which is a high-throughput se-
quencing, to identify the molecular arrangement of DNA base
pairs specifying the coding regions of a person’s genome also
referred to as the exome. While this is exciting, it may not
have clinical utility because the exome only comprises about
1 % of the entire genome [167].
When compared to the enormous literature on candidate
gene analysis (6120 studies) currently there is a paucity of
GWAS/WES studies relevant to addiction liability (239 stud-
ies). A commentary by Hall et al. [168] fromNIDA and others
have argued that candidate gene analysis may be wrong.
However, they do suggest the following from many GWAS
studies: (1) addiction is highly polygenic, each allelic variant
contributing in a small, additive (counting) amount to addic-
tion liability; (2) classes of genes (such as reward cir-
cuitry based genes) are most important in explaining
Table 10 GABA beta subunit 3 (a sampling)
Polymorphism(s) Study findings References Comments
GABA A receptor beta3 subunit gene
(GABRB3)
The G1- alleles of the GABRB3 in COAs
were significantly higher than non COAs
Namkoong
et al.
(2008)
In the same study the frequency of the A1+
allele at DRD2 in the COAs was
significantly higher than non COAs
beta 3 subunit m
RNAs
The levels of the beta 2 and beta 3 subunit
mRNAs remains elevated at 24 h
withdrawal from chronic ethanol. Chronic
ethanol treatment increased the levels of
both of these polypeptides in cerebral
cortex
Mhatre and
Ticku
(1994)
Chronic ethanol administration produced an
up-regulation of the beta-subunit mRNA
and the polypeptide expression of these
subunits in rat cerebral cortex
A1+ (A1A1 and A1A2 genotypes) and A1−
(A2A2 genotype) alleles of the DRD2 and
G1+ (G1G1 and G1 non-G1 genotypes)
and G1− (non-G1 non-G1 genotype)
alleles of the GABRB3 gene,Study
involved Mood-related alcohol
expectancy (AE) and drinking refusal self-
efficacy (DRSE) were assessed using the
Drinking Expectancy Profile.
Patients with the DRD2 A1+ allele,
compared with those with the DRD2 A1−
allele, reported significantly lower DRSE
in situations of social pressure. Similarly,
lower DRSE was reported under social
pressure by patients with the GABRB3
G1+ allele when compared to those with
the GABRB3 G1− alleles. Patients with
the GABRB3 G1+ allele also revealed
reduced DRSE in situations characterized
by negative affect than those with the
GABRB3 G1− alleles. Patients carrying
the GABRB3 G1+ allele showed stronger
AE relating to negative affective change
(for example, increased depression) than
their GABRB3 G1− counterparts
Young
et al.
(2004)
Molecular genetics research has identified
promisingmarkers of alcohol dependence,
including alleles of the D2 dopamine
receptor (DRD2) and the GABAA
receptor beta3 subunit (GABRB3) genes
Dinucleotide repeat polymorphisms of the
GABA(A) receptor beta 3 subunit gene
were compared to scores on the General
Health Questionnaire-28 (GHQ)
Analysis of GHQ subscale scores showed
that heterozygotes compared to the
combined homozygotes had higher scores
on the somatic symptoms (P=0.006),
anxiety/insomnia (P=0.003), social
dysfunction (P=0.054) and depression
(P=0.004) subscales
Feusner
et al.
(2001)
The study indicates that in a population of
PTSD patients, heterozygosity of the
GABRB3major (G1) allele confers higher
levels of somatic symptoms, anxiety/
insomnia, social dysfunction and
depression than found in homozygosity
GABRB3 major (G1) allele and DRD@ A1
allele
A significant progressive increase was
observed in DRD2 A1 allelic prevalence
(P=3.1×10(−6)) and frequency (P=2.7×
10(−6)) in the order of non-alcoholics, less
severe and severe alcoholics. In severe
alcoholics, compared to non-alcoholics, a
significant decrease was found in the
prevalence (P=4.5×10(−3)) and
frequency (P=2.7×10(−2)) of the
GABRB3 major (G1) allele. Furthermore,
a significant progressive decrease was
noted in G1 allelic prevalence (P=2.4×10
(−3)) and frequency (P=1.9×10(−2)) in
non-alcoholics, less severe and severe
alcoholics, respectively
Noble et al.
(1988)
In sum, in the same population of non-
alcoholics and alcoholics studied, variants
of both the DRD2 and GABRB3 genes
independently contribute to the risk for
alcoholism, with the DRD2 variants
revealing a stronger effect than the
GABRB3 variants. However, when the
DRD2 and the GABRB3 variants are
combined, the risk for alcoholism is more
robust than when these variants are
considered separately
Mol Neurobiol
Table 11 MOA-A (a sampling)
Polymorphism(s) Study findings References Comments
MAOA genotype Significant three-way interactions, MAOA
genotype by abuse by sex, predicted dysthymic
symptoms. Low-activity MAOA genotype
buffered against symptoms of dysthymia in
physically abused and multiply-maltreated
women. Significant three-way interactions,
MAOA genotype by sexual abuse by race,
predicted all outcomes. Low-activity MAOA
genotype buffered against symptoms of
dysthymia, major depressive disorder, and
alcohol abuse for sexually abused white
participants. The high-activity genotype was
protective in the nonwhite sexually abused group
Nikulina et al.
(2012)
This prospective study provides
evidence that MAOA interacts with
child maltreatment to predict mental
health outcomes
low-repeat MAOA allele Individuals with CUD had reductions in GMVin the
orbitofrontal, dorsolateral prefrontal, and
temporal cortex and the hippocampus compared
with controls. (2) The orbitofrontal cortex
reductions were uniquely driven by CUD with
low- MAOA genotype and by lifetime cocaine
use
Alia-Klein
et al. (2011)
Long-term cocaine users with the low-
repeat MAOA allele have enhanced
sensitivity to gray matter loss,
specifically in the orbitofrontal
cortex, indicating that this genotype
may exacerbate the deleterious
effects of cocaine in the brain
MAOA u-VNTR Girls, carrying the long MAOA u-VNTR variant
showed a higher risk of being high alcohol
consumers, whereas among boys, the short allele
was related to higher alcohol consumption
Nilsson et al.
(2011)
The present study supports the
hypothesis that there is a relation
between MAOA u-VNTR and
alcohol consumption and that this
relation is modulated by
environmental factors
30-bp repeat in the promoter region
of the monoamine oxidase-A
gene (MAO-A)
Significant associations between cold pain tolerance
and DAT-1 (P=0.008) and MAO-A (P=0.024)
polymorphisms were found. Specifically,
tolerance was shorter for carriers of allele 10 and
the rarer allele 11, as compared to homozygous
for allele 9, and for carriers of allele 4 (MOA) as
compared to homozygous for allele 3,
respectively
Treister et al.
(2009)
These results, together with the known
function of the investigated candidate
gene polymorphisms, suggest that
low dopaminergic activity can be
associated with high pain sensitivity
and vice versa
The Revised Psychopathy Checklist
(PCL-R) has shown a moderate
association with violence and as
such studied with MAOA
genotyped alcoholic offenders
The PCL-R total score predicts impulsive
reconvictions among high-activity MAOA
offenders (6.8 % risk increase for every one-point
increase in PCL-R total score, P=0.015), but not
among low-activity MAOA offenders, whereas
antisocial behavior and attitudes predicted
reconvictions in both genotypes (17 % risk
increase among high-activity MAOA offenders
and 12.8 % increase among low-activity MAOA
offenders for every one-point increase in factor 2
score)
Tikkanen et al.
(2011)
Results suggest that the efficacy of
PCL-R is altered by MAOA
genotype, alcohol exposure, and age,
which seems important to note when
PCL-R is used for risk assessments
that will have legal or costly
preventive work consequences
Genotyping of two functional
polymorphisms in the promoter
region of the serotonin transporter
and monoamine oxidase-A,
respectively, (5-HTT-LPR and
MAOA-VNTR), was performed
in a group of women with severe
alcohol addiction.
Within the group of alcoholics, when the patients
with known co-morbid psychiatric disorders were
excluded, aggressive anti-social behavior was
significantly linked to the presence of the high
activity MAOA allele
Gokturk et al.
(2008)
The pattern of associations between
genotypes of 5-HTT-LPR and
MAOA-VNTR in women with
severe alcoholism differs from most
corresponding studies on males
The MAOA gene presents several
polymorphisms including a 30-bp
VNTR in the promoter region
(MAOA-uVNTR). Alleles with
3.5 and 4 repeats are 2–10 times
more efficient than 3-repeat allele.
The results suggest that the 3-repeat allele is
associated to: (1) alcohol dependence (P<0.05);
(2) an earlier onset of alcoholism (P<0.01); (3)
comorbid drug abuse among alcoholics
(P<0.05); and (4) a higher number of antisocial
symptoms (P<0.02)
Contini et al.
(2006)
Results confirmed reports showing an
association of the low activity 3-repeat
allele of MAOA uVNTR
polymorphism with substance
dependence and impulsive, antisocial
behaviors. These findings in a different
culture support influence of MAOA-u
VNTR in psychiatric illness
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both risk and resilience to all addictions and (3) sub-
stantial genetic heterogeneity exists, and there is a con-
vergence of GWAS signals on particular candidate-
genes.
It is well-known that the action of psychoactive drugs
primarily affects synaptic neurotransmission. Reynolds et al.
[169] correctly suggest that specific genes for neurotransmitter
receptors and transporters have provided strong candidates in
Table 12 Dopamine D3 (a sampling)
Polymorphism(s) Study findings References Comments
The genotypes of the BDNF
Val66Met and DRD3 Ser9Gly
polymorphisms. BDNF regulates
expression of D3.
Logistic regression analysis showed a significant
main effect for the Val/Val genotype of the
BDNF Val66Met polymorphism (P=0.020),
which predicted bipolar-II patients. Significant
interaction effects for the BDNF Val66Met
Val/Val genotype and both DRD3 Ser9Gly
Ser/Ser and Ser/Gly genotypes were found
only in bipolar-II patients (P=0.027 and
0.006, respectively)
Lee et al.
(2012)
Evidence that the BDNF Val66Met and DRD3
Ser9Gly genotypes interact only in bipolar-II
disorder (hypomania) and that bipolar-I
(Mania) and bipolar-II may be genetically
distinct
D3R KO mice. The possible interaction between morphine-
induced tolerance and D3 receptors has not
been investigated. Compared with wild-type
(WT) mice, the dopamine D3 receptor
knockout (D3R KO) mice showed
pronounced hypoalgesia. The D3R KO mice
clearly developed lower morphine-induced
tolerance and showed attenuated withdrawal
signs compared with the WT mice
Li et al.
(2012)
These results suggest that D3 receptors regulate
basal nociception and are involved in the
development of morphine-induced tolerance
and withdrawal
DNA microarrays of two different
alcohol-preferring rat lines (HAD
and P) and D3 receptors.
Data revealed an up-regulation of the dopamine
D3 receptor (D3R) after 1 year of voluntary
alcohol consumption in the striatum of alcohol
preferring rats that was confirmed by qRT-
polymerase chain reaction
Vengeliene
et al.
(2006)
Long-term alcohol consumption leads to an up-
regulation of the dopamine D3R that may
contribute to alcohol-seeking and relapse. We
therefore suggest that selective antagonists of
this pharmacological target provide a specific
treatment approach to reduce alcohol craving
and relapse behavior
Gly9 homozygotes in comparison to
Ser9 carriers of D3 receptor gene.
German descent and have found diminished
parietal and increased frontal P300 amplitudes
in Gly9 homozygotes in comparison to Ser9
carriers. Further studies should address the
direct role of the DRD3 Ser9Gly
polymorphism in attenuated P300 amplitudes
in psychiatric disorders like schizophrenia or
alcoholism
Mulert
et al.
(2006)
An important reason for the interest in P300
event-related potentials are findings in patients
with psychiatric disorders like schizophrenia
or alcoholism in which attenuations of the
P300 amplitude are common findings
Dopamine receptor D3 gene BalI
polymorphism.
Patients above the median value for cognitive
impulsiveness (one of the three dimensions of
the Barratt scale) were more frequently
heterozygous than both alcohol-dependent
patients with lower impulsiveness (OR=2.51,
P=0.019) and than 71 healthy controls (OR=
2.32, P=0.025)
Limosin
et al.
(2005)
The D3 Receptor gene has been associated with
addictive behaviors especially impulsiveness
Bal I polymorphism at the DRD3
gene
Patients with a sensation-seeking score above 24
were more frequently homozygotes for both
alleles than patients with a sensation-seeking
score under 24 (P=0.038) or controls (P=
0.034)
Duaux
et al.
(1998)
These results suggest that the DRD3 gene may
have a role in drug dependence susceptibility
in individuals with high sensation-seeking
scores
mRNA of both DRD2 and DRD3
gene expression
After a chronic schedule of intermittent bingeing
on a sucrose solution, mRNA levels for the D2
dopamine receptor, and the preproenkephalin
and preprotachykinin genes were decreased in
dopamine-receptive regions of the forebrain,
while D3 dopamine receptor mRNAwas
increased. The effects of sugar on mRNA
levels were of greater magnitude in the nucleus
accumbens than in the caudate-putamen
Spangler
et al.
(2004)
Striatal regions of sugar-dependent rats show
alterations in dopamine and opioid mRNA
levels similar to morphine-dependent rats
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pharmacogenetic research in psychiatry. Moreover, there
are many inconsistencies between candidate gene and
GWAS studies. Reynolds further suggests that consisten-
cies have accumulated through candidate gene studies in-
volving the dopamine D2 receptor; serotonin transporter;
and GABA dysfunction in mental illness. Moreover, Han
et al. [170] reported that following GWAS, functional
enrichment analysis revealed specific genes to underlie
alcohol risk such as cation transport, synaptic transmission,
and transmission of nerve impulses representing meaning-
ful biological processes. In agreement, Uhl et al. [171]
suggest that following GWAS, clusters of SNPs within
selected genes display 10(−2)>P>10 (−8) associations
with dependence in many independent studies. Important-
ly, along these lines, specific candidate genes associated
with substance dependence phenotypes, for example, in
Native Americans, these include OPRM1, CRN1, COMT,
GABA2, MAOA, and HTR3-B [172]. In a cross-species
GWAS study to access risk genes, in alcoholism, it was
found that 47 genes associated including GABA, signaling
pathway and cell communication [173]. In one study using
GWAS and factor analysis, Agrawal et al. [174] found a
high loading (0.89) for alcohol craving and convergence
resulted in an association of SNPs in DRD3 and craving.
While there are many more examples showing promising
convergence between GWAS and candidate gene analyses,
albeit others showing no convergence, Li et al. [175] per-
formed a meta-analysis of addiction candidate gene associa-
tion studies and GWAS to investigate functional mechanisms
linked to addiction risk. When they compared the lists of
genes identified by molecular biological studies of drug-
related genes and those by association studies, they observed
significantly higher participation in the same gene interaction
networks than expected by chance. This work is underscored
by Li’s earlier work, the KARG analysis that evaluated 1,500
human genes regulating addictive behaviors and found that
these genes significantly impact glutaminergic and dopami-
nergic pathways [176].
GWAS studies in psychiatry frequently fail to explain a
large proportion of variance and non-replication of individual
SNPs. Derringer et al. [177] utilizing a “selective scoring”
whereby variants (273 SNPs) from eight dopamine-related
genes for association with cocaine dependence were consid-
ered. They identified a four SNP score significantly associated
with the variance. They suggested that (1) limiting SNPs to
genes of theoretical importance improves the chances of iden-
tifying replicable effects (2) utilizing this scoring approach
which considers top-associated SNPs in the aggregate can
reveal replicable effects that are too small to be identified at
the level of individual SNPs. Along with these precautions we
also propose the utilization of “super controls” to eliminate
cross contamination of having a control phenotype that
also carries the associated disorder especially when con-
sidering the complex nature of RDS. Also in developing
GARS we are cognizant that the proposed test only
provides risk stratification and not actual diagnosis of
any disorder including RDS. Most importantly, full com-
prehension of “psychiatric pharmacogenomics” will un-
doubtedly involve epigenetic factors, such as DNA his-
tone modifications, for example, methylation and or acet-
ylation that can affect responses to drugs and polymor-
phic antecedents for either vulnerability or resilience to
reward behaviors like RDS, as well as, GWAS conver-
gence to candidate genes [178–185].
Moreover, the utilization of GARS in the clinic has benefits
other than just risk stratification, such as, potential therapeutic
targets, reduced denial, medical monitoring, for example, in
terms of pharmacogenomic tagging [186]. Moreover, we are
cognizant that certain ethnic groups will have different rates of
polymorphic genes as well different rates of gene polymorphic
frequencies [187], and we are developing an algorithm to
address this issue involving weighting. In addition, we are
Table 13 GARS panel
Gene Allele Prime function
Dopamine D1 Receptor 48G Regulation of dopamine release in accumbens
Dopamine D2 Receptor (ANKKI/DRD2) Taq I A1 Controls synthesis of dopamine D2 receptors
Dopamine D3 Receptor (DRD3) C Carriers sensitive to cocaine; opioids, alcohol
and nicotine
Dopamine D4 Receptor (DRD4) 7R Pre-disposed to novelty seeking and ADHD
Dopamine Transporter (DAT1) 9R Fast transport of synaptic dopamine back into
pre-neuron leading to hypodopaminergic trait.
Serotonin Transporter (HTTLPR) S Fast transport of serotonin back into neuron
Mu-opiate Receptor (OPRM1) G Predisposes to heroin addiction and pain sensitivity
GABA B3 Receptor (GABAR3) 181. Predisposes to anxiety disorders
Mono-Amine Oxidase A (MAO-uVNTR) 4R Fast catabolism of mitochondria dopamine
Catecholamine Methyl-Transferase
(COMT-vall58met)
G Val substitution leads to fast catabolism of synaptic
dopamine leading to RDS
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analyzing additional data including a total of 393 subjects
derived from 9 treatment centers of which 320 have taken
the Addiction Severity Index (ASI).
The problem of GWAS is that a general conclusion from
GWAS is that most polymorphisms confer little risk increments
and explain a small portion of heritability. One example is that 40
loci have been associated with human height, with a known
heritability of about 80 %, but those total variants explain only
5% of the phenotypic variance. It has been suggested that amain
problem with GWAS is the need for a level of multiple statistical
comparisons that are unprecedented in biology, with stringent
analyses to achieve genome-wide significance [186]. In fact,
Belcher et al. [188] suggest there is clear evidence to support a
genetic basis for SUD. While these authors consider personality
as an appropriate endophenotype, we argue that the real
endophenotype is RDS aswe suggested in the generational study
[18]. Certainly, there are a number of studies showing enhanced
relapse with specific polymorphisms such as carriers of the
DRD2 A1 allele as only one example [189]. Finally, as we
pointed out herein, there are fairly recent studies showingGWAS
convergence to candidate genes suggesting the continued impor-
tance of the candidate approach to identify genetic risk
[166–177].
Conclusion
We encourage further work in the area of psychiatric genetics
like GARS and new technology like CARD to track patients
during recovery more intensively. While GARS may not be
perfect as yet andmore research is necessary in the near future,
we should not at this point “throw out the baby with the bath
water.” Utilization of these suggested new technologies
should impact the “revolving door” and secure significant
reduction in relapse.
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